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ABSTRACT  
Background: Surgical site infection is a common complication after caesarian section. Correct 
identification of risk factors for SSI is key to the design and implementation of effective preventive 
strategies. Preventive strategies are costly, however, and should be implemented up to the point where the 
costs per surgical site infection avoided are less than the benefits gained per surgical site infection. This 
means that only cost effective strategies should be embarked on.   
Objectives: To identify risk factors of surgical site infections and the associated costs and to perform a 
cost-effectiveness analysis on extending antibiotic prophylaxis to all women undergoing caesarian section 
in Norway. 
Study Group: Women who under-went caesarian section in Norway and were captured by the Norwegian 
surveillance system for hospital-acquired infections (NOIS) between September 2012 and December 2014. 
Methods: Three analyses (risk analysis, cost analysis and cost-effectiveness analysis) were conducted 
from a hospital perspective. Logistic regression was used for the risk analysis, micro-costing for the cost 
analysis and decision analytical model for the cost-effectiveness analysis. Surgical site infection avoided 
was the measure of effect in cost effectiveness analysis. All costs were in Norwegian kroner (NOK, 2015). 
Results: A total of 19,796 women who underwent caesarian section were included in the study. The mean 
age was 31± 4. The rate of surgical site infections was 4.4% or 868 out of 19,796 caesarian sections. Data 
on 10 variables were analyzed and three of these were identified as independent risk factors of surgical site 
infections: (i) ASA score greater than III (OR 11.49; p-value 0.05; 95% CI 1.02 – 129.46), (ii) hospitals 
with bed capacity 250 – 500 (OR 1.44; p-value 0.04; 95% CI 1.01–2.06) and (iii) secondary level hospitals 
(OR 2.30; p-value 0.00; 95% CI 1.36 – 3.89). 
The average cost of caesarian section not complicated with SSI was NOK 52,117. For caesarian section 
complicated with SSI, it was NOK 124,321.  The costs of SSI increased with the depth of infection. For 
superficial SSI, the costs were NOK 97,301, for deep SSI there were NOK 189,329 and for organ/space 
infections there were NOK 196,754. Prolonged length of stay accounted for 78% of all the costs and the 
least costs were for laboratory tests.  
The average cost per patient with the current antibiotic guidelines was NOK 55,634 while it was NOK 
55,231 if the antibiotic prophylaxis is given to all women undergoing caesarian section. The proportion of 
women with SSI was 5% and 4% for the current and extended guidelines respectively, representing a cost 
saving of NOK 40,300 per avoided SSI. The difference in costs and effects between the extended 
guidelines and the current guidelines was NOK 403, (95% CI: NOK -900 to NOK150) and 0.01, (95% CI: 
0.0025 to 0.012).   
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1. Introduction 
In Norway as in many other countries, the caesarian section rate (CSR) has been rising from 
2.5% in 1972 to 17 % in 2012
1
 (Figure 1). A high CSR, defined as the number of caesarean 
deliveries over the total number of live births
2
 has resource implications for the health care 
sector. For example, the WHO report (2010) estimated that the Norwegian CSR of 17 % 
translates into 928 unnecessary caesarian sections (CS) with an estimated cost of $ 1,915 
956
1
.The rising CSR are also associated with a high risk of maternal complications such as 
surgical site infections (SSI)
2
. According to Mangram et al
3
 a patient with an SSI has a 
postoperative surgical infection localized to the part of the body where the surgery took 
place. Such a patient is likely to suffer from the cost of human suffering and pain and lose out 
on productivity. On the health care sector, SSI imposes considerable economic burden in 
terms of extended hospital stay (LOS), nursing care costs, extra diagnostics and 
medical/surgical interventions costs
4
.  
 
                Figure 1: Increase in proportion of caesarian sections in Norway: 1967 – 2011                                                
(Source: Folkehelseinstituttet, http://www.fhi.no/artikler/?id=52705) 
Understanding the risk factors for SSI and the costs associated with it is fundamental to the 
development of effective preventive strategies. One such strategy is the use of antibiotic 
prophylaxis in caesarian section. However, since there are economic consequences to the 
implementation of such preventive strategies’, conducting cost-effective analysis helps health 
care decision-makers to choose cost-effective programs.   
                                                             
1 Source: World Health Report (2010) Background Paper, No 30 
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From the Norwegian Health care perspective, the exact extent of the economic burden of SSI 
after CS on the nation’s health care system is unclear. What seems clear though is that SSI 
following CS imposes significant costs on the Norwegian health care system. In order to 
ascertain the exact extent of the economic burden these infections impose on the health care 
system, a comprehensive analysis of costs associated with SSI after CS needs to be 
conducted. By conducting a cost analysis, this study will generate cost estimates that might 
ultimately influence health care policy decisions such as guideline formulation and infection 
prevention strategies in Norway. Secondly, even though this study may not be considered 
comprehensive enough owing to its limitations in perspective, costs inclusion and method of 
cost estimation, it will add to the knowledge of cost analysis of SSI that follows CS in 
Norway and continue as a foundation on which future studies on costs associated with SSI 
can build upon.  
This study will focus mainly on health care related costs of SSI after CS. Societal and patient 
related costs are beyond the scope of the study though factors (societal and patient related) 
that are pertinent to the study will be brought forward and discussed whenever necessary.  
The study is divided into three parts – risk analysis, cost analysis and cost effectiveness 
analysis. It is outlined as follows: Chapter 2 discusses the theoretical background of the 
study. Chapter 3 presents the data and methods used in the study. The findings of the study 
are then presented in the chapter on results (chapter 4). Chapter 5 discusses these findings 
and the study ends with reiterating the importance of identifying the risk factors of SSI after 
CS, estimating the costs associated with SSI after CS and performing a cost-effectiveness 
analysis for preventive strategies.  
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2. Theoretical Background 
In this chapter I present the theoretical foundations of the study. The basics of CS such as the 
rate, indications and complications of CS are discussed first. Followed thereafter is a 
discussion on SSI as one of the post-operative complication. Then the cost consequences of 
SSI after CS are deliberated before the chapter ends with a discussion on methods of 
economic evaluation.  
2.1 Caesarian section  
Cesarean delivery is defined as the delivery of a fetus through a surgical incision made 
through the abdominal wall (laparotomy) and the uterine wall (hysterotomy)
5
.  This definition 
ignores the status of the fetus, whether alive or dead and only considers the location of the 
fetus. From an anatomical point of view, the surgeon has to cut through three major layers of 
the abdomen before reaching the baby (Figure 2). 
Figure 2. Anatomical outline of the layers of the abdominal wall                                                                                       
(Source:http://stefanwirawan1.hubpages.com/hub/Instant-anatomy-Anatomy-lecture-made-easy-Anterior-abdominal-wall#slide6380902) 
The first layer to be incised is the skin with the subcutaneous tissue and fascia underneath it. 
The second is a layer of muscles and then the lining of the abdominal cavity, called the 
peritoneum, which encloses the abdominal organs. The uterus lies right below the 
peritoneum. It is a muscular sac enclosing the baby and the surgeon makes either a transverse 
or vertical incision through it to deliver the baby
6
.  
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Cesarean sections are generally defined as elective when they were performed at least 8 hours 
after the decision to operate is made
7
. Usually this is made before the onset of labor and with 
intact membranes. Conversely cesarean sections are defined as emergency when not 
planned
6-9
. Often this happens during labor or with ruptured membranes.  
2.1.1 Caesarian section rate  
Over the years the global rate of CS has been steadily increasing and this increase has 
generated a number of controversies, among them is the issue of what the optimum rate of CS 
is. Many explanations have been put forward in an attempt to explain the CS inflation: 
Improved surgical practice, increasing maternal age, more multiples babies, maternal request, 
the hostile obstetric medical-legal environment and physician convenience and economic 
benefit of care givers
1, 10
.  
Global concerns over the steady increase in the rate of CS are mainly derived from the fact 
that higher CS rates do not seem to provide additional health gains but may increase maternal 
risks, have implications for future pregnancies and have resource implications for health 
services
2
. For this reason, the WHO set an upper threshold of 15% CSR. Although the global 
CSR are estimated around 1.8% – 42%, the rates are unevenly distributed and follow the 
health care inequity pattern of the world with low rates in low income settings, and moderate 
or high rates in middle and high income settings
2
. In Norway, a similar trend is seen with the 
CSR varying widely (6% to 20%) between different obstetric departments
7
. The variations 
are explained by the fact that larger hospitals are often referral hospitals, which receive many 
mothers with increased risk of complications and thus increased need for cesarean delivery
2
. 
On a global scale, comparable studies with other countries reveal that the Norwegian CSR 
lies in the lower segments
2
.  
2.1.2 Indications for caesarian section 
Indications for caesarean delivery vary depending on the clinical situation, resource 
availability and individual surgical management techniques
5
. Initially CS was clinically 
indicated as a lifesaving procedure for the mother and the baby. However, non-medical 
indications centered mostly on legal and socio-economic motives have in the recent past been 
recognized as acceptable indications for performing CS
1, 11
. Considering that there are risks 
and benefits involved, these new indications have stirred an ongoing debate among medical 
                                                             
2 Adopted from http://www.fhi.no/artikler/?id=52705. Last viewed 18.02.2015 
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professionals and women themselves. Caesarian delivery on maternal request (CS – MR) for 
instance raises a lot of emotive, contemptuous and economic questions to health care policy 
makers, medical professionals and the women groups
1, 11
. Whereas medical professionals are 
obliged to perform CS when medically indicated and women have the right to choose the 
method of delivery, health care policy makers consider the cost effectiveness of performing 
an extra CS.   
Even though indications for CS have evolved tremendously, the two most frequent 
indications for emergency cesarean deliveries in Norway are fetal stress and failure to 
progress, while the most frequent indications for elective CS are previous cesarean delivery 
and maternal request
1
 (Table 1).   
Table 1 Distribution of First Choice indications for caesarian section in Norway (N=2778) 
 
(Source: Volume 188, Number 4 Kolås et al. 865 Am J Obstet Gynecol.) 
2.1.3 Surgical site infection as a complications of Caesarian Section  
Despite CS being viewed as a lifesaving procedure for both mother and baby, the study by 
Håger et al
7
 revealed that cesarean delivery is associated with complications in one of five 
women in Norway. Complications of CS can be maternal or fetal or affect both. Maternal 
complications are divided into intraoperative complications and postoperative complications. 
In the postoperative period, CS can complicate in many ways but the predominant 
complications are hemorrhage, thrombo-embolic complications and infections. 
7 
 
Post-operative infections can further be divided into Surgical Patient Infections (SPI) and 
SSI. According to Horan et al
12
, SPI are systemic and remote complicating infections that 
follow an operative procedure, and for this reason they are not classified among SSI. On the 
other hand, SSIs are defined as infections involving areas that were incised, opened or 
manipulated during an operative procedure
12
.  
2.2 Surgical Site Infections  
Surgical site infections are a heterogeneous group of complications that follow surgical 
interventions. The heterogeneity can be shown by the many ways SSIs are classified.  The first is 
the ASEPSIS score system, which is based on the clinical signs of infected wounds. It is an 
acronym for Additional treatment, Serous discharge, Erythema, Purulent exudate, Separation 
of deep tissues, Isolation of bacteria and Stay as inpatient prolonged over 14 days13. The 
Altemeier classification system is another classification system based on the level of risk of 
infection and classifies surgical wounds as clean, clean- contaminated and contaminated or 
dirty. The CDC classification is based on anatomical location and pathophysiological 
changes and is endorsed by the various National Nosocomial Infections Surveillance systems 
(NNIS) including the Norwegian Surveillance System for Healthcare-Associated Infections 
(NOIS) 
12, 14-17
.  
Surgery specific classification of SSI considers independent surgical procedures such as SSI 
after caesarian section, cholecystectomy, hip replacement, cardiac surgery etc. The study 
focus is on SSI after CS. SSIs are also defined with a time frame in mind, during initial 
admission (often 2-3 days post-op), at 30 days post-operative period or at one year if an 
implant is in place. Further classification considers the type of bacteria involved with gram 
positive cocci (Staphylococcus aureus and Streptococcus pyogenes) and gram negative bacilli 
(Enterobacteriaceae) being particularly classified as the most common and virulent strains18. 
Adopting a reliable and consistent classification for SSI is crucial for three reasons: (i) It 
defines a common language and provides a standardized assessment tool for physicians or 
infection control practitioners to assess and classify SSI, (ii) It enables the surgical team to 
provide the appropriate surgical care and (iii) it enables accurate estimation of SSI associated 
costs since costs are directly related to the type of infection. Based on these reasons, SSI after 
CS will be discussed under the CDC classification
3
.  
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2.2.1 The CDC classification of SSI 
The CDC (1992) classification of SSI distinguishes incisional SSI from organ/space SSI 
(Figure 3). Incisional SSI are further divided into superficial incisional SSI, comprising only 
the skin and subcutaneous tissue and deep incisional SSI, involving deep soft tissues of the 
incision (fascia and muscle layers)
12
.For superficial incisional SSI, the infection, in addition 
to involving only the skin and subcutaneous tissues must occur within 30 days after the 
operation. Additional criteria for deep incisional SSI include infections occurring 30 days 
into the post-operative period without implants or within one year if implants are in place.   
The term Organ/space SSI encompass infections in any anatomical organs or spaces besides 
the incision that were either opened or manipulated during the operation
12
. With regards CS, 
endometritis and intra-abdominal abscesses are typical examples of an organ/space SSI. 
These are site-specific SSI with the same additional time criteria as deep incisional SSI
12
 
Whilst the CDC classification of SSI was done for surveillance purposes the study will in 
addition use it for the purpose of analyzing cost estimates of SSI following CS. 
      
                          
Figure 3 Schematic of SSI anatomy and appropriate classification  
(Source:  Infection Control and Hospital Epidemiology, Vol. 13, No. 10 (Oct., 1992), pp. 606-608)                                                                
 2.2.2 Norwegian Surveillance System for Healthcare-Associated Infections (NOIS- SSI) 
The NOIS register is a mandatory surveillance system for HAI in Norway. The NOIS system 
aims to conduct a systematic collection, analysis, interpretation, and dissemination of data 
about the occurrence of SSI after CS in the hospitals
19
. In additional to CS, the NOIS-SSI 
register has the following infections under its surveillance: coronary bypass, hip arthroplasty, 
9 
 
cholecystectomy and colon surgery. 
It is founded on the CDC’s NNIS system and became set up in Norway as a regulatory 
system in 2005. By NOIS regulation, all Norwegian hospitals participate in the surveillance 
system and govern the collection, collation, storage and use of data, and the submission of 
data to the Norwegian Institute of Public Health (NIPH)
20
. The three key features of NOIS 
are (i) It is national and mandatory, and therefore provides a broader and better overview of 
the country’s infection status, (ii) utilizes highly automated data collection and harvesting 
systems and (iii) the NOIS has an active post discharge surveillance (PDS) for 30 days (1year 
for implants) after surgery
20
. Data are collected before, during, and 30 days after CS (Figure 
4). The importance of this timing is twofold. To begin with, most SSI appears after discharge 
from hospital. Urban et al
21
 estimates these post discharge infections to range from 47% to 84 
%. Secondly, SSI diagnosed after discharge were more costly to treat than SSI diagnosed 
during the initial admission period
22
.  
Geographically, Norway is divided into four Regional Health Trusts (RHT) or Regionalt 
helseforetak (RHF) (Appendix 1). All the four RHT fall directly under the Ministry of Health 
and Care Services. The Helse Sør-Øst RHF is the largest of the four RHT and others include 
Helse Nord RHF, Helse Vest RHF and Helse Midt-Norge RHF. 
 
(Source: American Journal of Infection Control xxx (2013) 1-6)                                                                                                          
Figure 4 Points in time for collection of information during 30-day follow-up in NOIS-SSI.  
All hospitals in Norway have electronic Patient Administration Systems (PAS) and 
Computerized Infection control Modules (ICM) that harvest data from the hospitals’ existing 
systems or the surgery scheduling systems. Even though these systems harvest almost all the 
background and explanatory variables, the outcome variable - infection status, is manually 
entered by the health staff
20
.  To ensure compliance, the NOIS register is a regulatory 
instrument and all hospitals in Norway are by law required to submit data to NIPH. The 
NOIS-SSI has around 162 variables but not all are relevant to the study, therefore only 10 
10 
 
independent variables will be used.  
Studies show that surveillance of SSI after CS with feedback to the surgeon results in reduced 
infection rates (20%-30%), aids in identifying and evaluating preventive measures and is the 
basis for evidenced based strategies in infection control
3, 19, 20, 23, 24
.  Therefore the NOIS 
report on SSI after CS is fed back to the hospitals after undergoing a quality assurance at 
NIPH. The hospitals in turn are expected to convey their own data back to the departments, 
surgeons, and hospital administrators. 
2.2.3 Risk factors for SSI after CS 
In the strictest terms, a risk factor refers to a variable that has a significant, independent 
association with the development of SSI after a specific operation
3
. Risk factors are therefore 
identified using multivariate analysis. In general terms, the use of the term risk factor has 
been extended to include both patient and operational features which are not necessarily 
independent predictors but are associated with the development of SSI in bivariate analysis.   
Knowledge of risk factors is fundamental to the prevention of SSI and the development of 
cost saving strategies in health care systems. Risk factors for post-CS SSIs can be classified 
as intrinsic or extrinsic. Intrinsic risk factors are patient related while extrinsic risk factors are 
related to the obstetric and operational factors
9
. A review of past studies on risk of SSIs after 
CS reveals that a multitude of factors predispose women to developing post-CS SSI
6, 8, 24, 25
. 
Intrinsic risk factors include, among others, age, race, body mass index (BMI), American 
Society of Anesthesiology (ASA) score, gestational diabetes, Sexually Transmitted Infections 
(STI) and use of alcohol and tobacco. Extrinsic factors are even more numerous and include 
obstetric related: previous CS, number of vaginal examinations before operation, duration of 
labor, gestational age at delivery and presence of vaginal discharge or bleeding, Operational 
related: urgency of operation (elective or emergency), type of skin and uterine incisional 
(vertical or lower segment), type of skin closure (staples or sutures), receipt of antibiotic 
prophylaxis, type of anesthetic technique (General or regional anesthesia), volume of blood 
loss and level of surgeon and type of hospital.  
Another way of assessing the risk status of women undergoing caesarian deliveries is the use 
of the NNIS risk index. The CDC’s NNIS risk index is an internationally recognized system 
of stratifying the risk of post-CS SSI. It is based on three major factors: (i) the American 
Society of Anesthesiologists’ (ASA) classification of the patient’s physical status >2 (ii) the 
11 
 
duration of the surgical procedure > 75
th
 percentile (1 hour for CS) and (iii) the wound 
classification system that reflects the degree of contamination >2 (contaminated or dirty). The 
risk of SSI increases with increasing risk index score
9
. For CS, modified wound 
classifications are used that take into consideration membrane rupture and presence of labor. 
According to Tran
26
 “Cesareans are classified class I if there is no rupture of membranes or 
labor, class II if there is less than 2 hours of rupture of membranes without labor or labor of 
any length with no rupture of membranes, class III for rupture of membranes greater than 2 
hours, and class IV for purulent amniotic fluid”. Rupture of membranes duration is the 
interval, in hours, between recorded timing of rupture of membranes and surgical incision
26
.  
2.2.4 Prevention and treatment of SSI after CS 
The possibility of developing a post-CS SSI is represented by the proportion of caesarian 
deliveries that result in infection and conventionally this is expressed in percentage
27
.  In 
Norway, Eriksen et al
24
 found that the incidence rate of SSI after CS in Norway was 8.3 % in 
2007. Estimating the rate of SSI after CS is important for assessment of merits and demerits 
of adopting caesarean section as a delivery method, and for evaluating the choice of 
preventive measures
24
.  
There exist several preventives strategies against SSI after CS and the provision of antibiotic 
prophylaxis is one of them. However, not every patient due for CS receives antibiotic 
prophylaxis in Norway and studies show that around 25% of CSs are not given antibiotic 
prophylaxis
28
. The general practice in most Norwegian hospitals is that antibiotic prophylaxis 
is not given in elective CS. The Norwegian guidelines in clinical obstetrics recommend the 
use of antibiotic prophylaxis in the form of a single dose of ampicillin or first generation 
cephalosporin in emergency CS or special situations such as prolonged operation or 
excessive hemorrhage. This is contrary to the Cochrane guidelines which recommend 
antibiotics prophylaxis to all CS regardless of urgency, risk or duration of surgery. 
The management of SSI after CS depends on the depth of the infection. Because superficial 
incisional post-CS SSI involve only the skin and subcutaneous tissues, the common 
interventions needed are the removal of sutures and drainage of the infected area, with or 
without antibiotics
29
. The prime cost drivers are relatively few and include costs for GP visit, 
wound dressings and occasionally cost for antibiotics and analgesics. Superficial incisional 
post CS SSIs are by far the most common type encountered in clinical practice
9, 14
.  
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Deep incisional post-CS SSI affect the facial and muscles and because of the depth of the 
infections, these SSI require repeated debridements and sometimes extensive wound 
reconstruction surgeries
29
. Likewise, deep incisional post-CS SSI attracts more costs than 
superficial incisional SSI. Additional costs arise from extended re-hospitalization, increased 
diagnostic tests and repeated surgical interventions
29
.  
The organ/space post-CS SSI are by far the most severe and attract more costs
29
. These 
infections require prolonged hospitalization and often multiple re-operations
29
.   
2.3 Economic burden of SSI after CS  
There exists a uniform recognition that SSI presents a major economic cost and high price of 
human suffering
29
. Indeed studies have demonstrated a clear relationship between SSI on one 
hand and the amount of medical interventions and associated health-care costs on the other
15, 
30-32
.  
2.3.1 Cost implications of SSI after CS 
The health care costs attributed to SSI following CS are significant. In England a study by 
Jenks et al
33
 reveal that a total of 4,694 hospital bed days, equivalent to 6.4 bed days per day 
were lost due to SSI during the period April 2010 and March 2012. Of these 142 days were 
attributed to post CS SSI. During the same period, a total of £2, 491 424 was aggregately 
attributed to SSI with £97, 021 attributed to post-CS SSI
33
. In the United Kingdom (UK) 
Mugfold et al
34
 estimated that costs per day and for each patient were, respectively, £56 and 
£716 higher for women with infection than for those without infection. In the United States, 
costs of SSI following CS are estimated at $3400 - $3700
31
. 
The trend is likely to be the same throughout the Scandinavia. For instance a report from 
Denmark, shows that the cost of care for all SSIs in general consumes 0.5% of the annual 
hospital budget
29
. In Norway, the exact cost of these SSI are not yet fully known, at least to 
my knowledge, though with the CSR approaching 17%, they are likely to be substantial.  
SSI adds to hospital costs in several other ways. For example, the prolonged use of 
antibiotics as part of the management of some SSI exposes women to the risk of developing 
antibiotic resistant SSI that cannot be treated by the commonly used antibiotics. This may 
occur because prolonged antibiotic use causes bacteria to metamorphose into drug – 
resistance strains such as Methicillin Resistant Staphylococcus Aureus (MRSA) and 
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Vancomycin Resistant Enterococcus (or VRE). The treatment of these drug resistance strains 
demands that women stay even longer in the hospital and undergo more repeated diagnostics 
and therapeutic interventions.  
2.3.2 Methods for estimating costs associated with SSI after CS 
There are two common methods of estimating costs associated with SSI after CS. The first is 
the top down method like the DRG system, which provide cost estimates for an average 
patient. The second is the bottom up method or micro costing. With this method, each 
procedure is identified, quantified and valuated to represent total health care resource usage. 
In the study, both methods are used.  
Fry et al
29
 states that using hospital charges is a common but flawed method of estimating 
those additional supplies and personnel required for care of the SSI. Besides the use of 
hospital charges, most studies use the mean costs per bed day instead of the marginal cost
29
. 
While the former is easy to calculate, the later provides more accurate way of estimating that 
additional costs of SSI after CS. Despite the shortcomings, most studies still use hospital 
charges to liberally estimate costs
21, 29, 35, 36
. Sources of cost information include hospital 
finance departments, financial databases or the accounting systems and previous studies. 
Other sources use clinical pathways that reveal and itemize resources consumed by women 
as they transit through the health care system. Market prices and national guidelines are often 
applied to these cost estimates.   
2.4 Economic Evaluation of Costs of SSI after CS  
Decision making in health care involves both costs and consequences. Drummond et al
37
 thus 
define economic evaluation as “the comparative analysis of alternative courses of action in 
terms of both their costs and consequences”. Implicitly economic evaluation is a tool for 
identifying, measuring, valuing and comparing costs and consequences of alternative 
actions
37
. 
2.4.1 Economic Evaluation 
The term economic evaluation is rightly used when the study compares at least 2 alternatives 
and includes both costs and consequences of the alternative courses of action
37
. Table 2 
illustrates the difference between partial economic evaluations, outcome description, cost 
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description, cost – outcome description, effectiveness evaluation, cost analysis and full 
economic evaluation: cost effectiveness, cost benefit and cost utility analyses.  
               Table 2. Distinguishing characteristics of health care evaluation       
 
 
 
 
                                      NO 
 
Is there comparison of two 
or more alternatives?                                               
                                    YES  
                          Are both costs and consequences of the alternatives examined?                                   
                                           NO                                                                             YES 
Examines only consequences  Examines only 
costs 
Examines both consequences and 
costs 
                                      PARTIAL ECONOMIC EVALUATION 
1 A. Outcome description 1B.Cost 
description 
 2. Cost- Outcome description 
         PARTIAL ECONOMIC EVALUATION FULL ECONOMIC EVALUATION 
3 A. Efficacy or Effectiveness 
evaluation 
3B.Cost 
Analysis 
4.  Cost effectiveness Analysis  
    Cost Benefit Analysis 
     Cost Utility Analysis 
   (Adopted from Drummond et al37: Methods for Economic Evaluation of Health Care Guidelines. ) 
Regarding the question of antibiotic prophylaxis in CS, economic evaluation enables decision 
makers to weigh the costs and consequences of extending the provision of antibiotic 
prophylaxis to all women undergoing caesarian section regardless of their risk status. 
Decision makers can then use the empirical evidence provided by economic evaluation to 
decide whether it is cost effective or not to include all women in the guidelines given the 
data.     
Results from a study can differ depending on the perspective adopted.  For example, one 
guideline may be considered cost effective when viewed from a health care perspective and 
not cost effective when considered from a societal perspective. For this reason Drummond et 
al
37
 recognize  five main perspectives of economic evaluation: the individual patient, the 
specific institution, the target group for specific services , the government in general and the 
societal perspective
37
.  
2.4.2 Cost Analysis 
Costs can be divided into direct and indirect costs.  According to Urban et al.
21
, direct costs 
are those costs that are measured and quantified easily. They include costs for prolonged 
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hospitalization, readmission, GP visits, additional surgery, prolonged antibiotic therapy, extra 
radiology and laboratory services etc. Indirect costs on the other hand are difficulty to 
quantify and include loss of productivity for the patient, relatives (care givers), cost of human 
suffering and pain, reduction of the quality of life etc. 
By definition, cost analysis is the analysis of comparative costs of alternative treatments or 
health care guidelines
37
. Since cost analysis is a comparative analysis, the comparator in this 
study is the baseline case of CS without a post-operative complication of SSI. According to 
Drummond et al
37
 costing has two elements: the measurement of the quantities of resource 
use (q) and the assignment of unit costs or prices (p), and the below equation depicts this 
relation:   
  𝑪𝒐𝒔𝒕𝒔 𝒐𝒇 𝑺𝑺𝑰 𝒂𝒇𝒕𝒆𝒓 𝑪𝑺 =   ∑ (𝑷𝒊 × 𝑸𝒊)
𝒏
𝒊=𝟏                                  [1] 
Where P = price of resources and Q = quantity of resources used, and N = number of cost 
drivers.                            
2.4.3 Cost Effective Analysis (CEA) 
Full economic evaluation is performed using one or a combination of any of the three types: 
Cost Effective Analysis (CEA), Cost Benefit Analysis (CBA) and Cost Utility Analysis 
(CUA). From the cost side, all three are similar. However, the difference stems from the way 
consequences are valued. The study will only employ CEA since the consequences are 
measured in a natural unit, which is SSI avoided. Secondly, the options (antibiotic 
prophylaxis for all CS and antibiotic prophylaxis for high risk CS) have a common effect or 
consequence (SSI) and lastly the options are independent guidelines of action whose effects 
do not interfere with each other. CEA is mostly used in budget constrained health care 
systems with limited range of available options.  The results of CEA may be stated either as 
cost per unit of effect or as effect per unit of cost
37
.  
Cost-effectiveness is expressed as an incremental cost-effectiveness ratio (ICER), which is 
the ratio of change in costs to the change in effects. The numerator of the ICER is the 
marginal difference of the mean cost of each treatment option and the denominator is the 
marginal mean difference of the effectiveness of each treatment option
37
.   
                                               𝑰𝑪𝑬𝑹 =  
∆𝑪
∆𝑬
 𝒐𝒓 
𝑪𝒏𝒆𝒘− 𝑪𝒄𝒐𝒎𝒑
𝑬𝒏𝒆𝒘− 𝑬𝒄𝒐𝒎𝒑
                     [2]                
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In the above expression, ∆𝐶 is the change in costs, ∆𝐸 is the change in effect, 𝐶𝑛𝑒𝑤 are the 
cost for the new guideline and 𝐶𝑐𝑜𝑚𝑝 are the costs of the comparator. 𝐸𝑛𝑒𝑤 is the effect of the 
new guideline whilst 𝐸𝑐𝑜𝑚𝑝 is the effect of the comparator.  
Incremental costs effectiveness ratios state the additional costs per additional unit of 
effectiveness and this way, they compare the incremental costs of the new alternative to the 
best-known alternative or comparator. For decision making in CEA, the ICER is compared to 
the maximum cost effectiveness ratio or the threshold ratio (𝑅𝑇). The threshold ratio 
represents the maximum willingness to pay (WTP) for one unit of effect. The best decision 
therefore is when the ICER is less than the threshold ratio or WTP, represented algebraically 
as: 
                                                                    
∆𝑪
∆𝑬
 <  𝑹𝑻                                     [3] 
An alternative method to ICER is the Net Monetary Benefit (NMB) of a guideline, expressed 
as 𝑅𝑇∆𝐸 −  ∆𝐶.  The NMB is the increase in effectiveness (∆𝐸) multiplied by the amount the 
decision maker is willing to pay per unit of increased effectiveness (𝑅𝑇), minus the increase 
in costs (∆𝐶)37. The decision rule with this method is that the best competing guideline 
should have a positive NMB, thus:  
                                                      𝑵𝑴𝑩 = 𝑹𝑻∆𝑬 −  ∆𝑪 > 𝟎                           [4] 
Certainly, if 𝑅𝑇 is estimated from individual’s actual willing to pay, then the NMB would be 
equivalent to calculations based on cost benefit analysis
37
.  
Another method to decision making in CEA is the use of Net Health Benefit (NHB). Using 
the NHB approach, a guideline is deemed cost effective if:  
                                                       𝑵𝑯𝑩 =  ∆𝑬 − (
∆𝑪
𝑹𝑻
)  > 𝟎                               [5]                           
This implies that for NHB to be positive, the health gains (∆𝐸) should be greater than those 
from investing the same resources in an alternative, marginally cost- effective guideline, with 
the cost effectiveness ratio 𝑅𝑇.  
Finally, the ICER can also be presented graphically as in cost effectiveness plane, with cost 
difference on the vertical-axis and effect difference on the horizontal-axis. As shown in 
Figure 5 below:   
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(Adopted from: David J. Cohen, Interpreting the Results of Cost-Effectiveness Studies. Volume 52, Issue 25,)  
             Figure 5. The cost effectiveness plane 
 Depending on the ICER results, the guideline of interest can fall in any of the quadrants. The 
northeast and southwest quadrants represents situations where the decision depends on the 
maximum cost effectiveness ratio the decision maker is willing to pay. Represented as a slope 
between competing guidelines, the maximum willingness to pay has to be compared to the 
ICER. For the northwest and southeast quadrants, the decision is quite straightforward. The 
southeast quadrant is the best choice since it represents situations where the intervention of 
interest is more effective and less costly whilst the northwest quadrant is where the 
intervention of interest is dominated and therefore not optimal.   
Results from studies on the cost effectiveness of antibiotic prophylaxis in caesarian section 
vary. On one hand, some studies have found antibiotic prophylaxis to be cost effective. For 
instance, Mugford et al
34
 found that the odds of wound infection were likely to reduce by 
50% - 70% when antibiotic prophylaxis is given. On the other hand, studies in Norway show 
that antibiotic prophylaxis was not correlated with the risk of SSI and thus not cost 
effective
24
. Another study by Eriksen et al
28
 showed marginal effects of antibiotic 
prophylaxis in preventing SSI. They found that antibiotic prophylaxis reduced the odds of 
developing an infection only in women with superficial infections.  
2.5 Study aims and research questions 
The aim of this study was to explore risk factors for and estimate costs of SSI following CS 
in Norway. Since SSI after CS require hospital resources, there is need to estimate how much 
of the hospital resources are used to treat women with SSIs. Only after estimating these costs 
are we able to estimate the cost effectiveness of infection prevention strategies. The main 
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hypothesis was therefore that SSI after CS impose significant economic burden on hospitals. 
Furthermore, the study will explore the possible significance of antibiotic use in elective CS.  
The study addresses the following questions: 
1.  What are the risk factors SSI after caesarian section in Norwegian hospitals? 
2.  What are the hospital costs related to SSI after caesarian section in Norway?  
3.  What are the costs and effects of antibiotic prophylaxis for high versus low risk CS? 
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3. Materials and Methods 
This chapter outlines the data and methods used to identify the risk factors of developing SSI 
after caesarian section, estimate the costs associated with SSI after caesarian section and 
analyze the cost effectiveness of extending antibiotic prophylaxis to all women undergoing 
caesarian section in Norway. All costs were presented in Norwegian Kroner (NOK) (USD 
1.00 ≈ NOK 8.00). 
3.1 Study Design 
The study was a retrospective register study based on the Norwegian Surveillance System for 
Healthcare-Associated Infections (NOIS) register and questionnaire from clinicians to 
identify the clinical management (pathway) for caesarian section with and without SSI. The 
NOIS –SSI register was the main source of data. It was chosen because it provided a sample 
that essentially included all women who underwent CS and those who developed SSI during 
the period September 2012 through December 2014. The study period (September 2012 – 
December 2014) corresponds to the time the NOIS register started recording data for the 
whole year. Earlier, data were captured only for a three months period each year. In addition, 
the period constitutes a complete 28 months study period and seasonal variations are likely to 
be captured. Comparing the NOIS register with the National Patient Register (NPR), which in 
essence captures all CS done in Norway, shows that the completeness of the NOIS register is 
rising and was 96.1 % in 2010
20
.  
3.2 Risk analysis 
All SSI reported were physician diagnosed and composed of all the three type: superficial, 
deep and organ/space infections. For the purpose of identifying the risk factors of SSI after 
CS, the primary dependent variable was the infection status, dichotomized as SSI or no SSI. 
The predictor variables were selected based on their clinical and economical relevance to the 
study. Data from the NOIS register and past studies on the risk of SSI after CS were also 
considered when selecting the predictor variables. Table 3 summarizes the variables used in 
the risk analysis. 
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Table 3.  Description and coding of the variables in NOIS register used in the study to identify potential 
risk factors of SSI after CS. 
Variable name Code                                                             Description of variables 
Infection status SSI                          
No SSI 
An ordinal variable with four ordinal points: no SSI, superficial SSI, deep SSI and organ/space SSI. For risk 
identification this variable was dichotomised into SSI and no SSI.  
Age  Number of years A continuous variable with a range in data set of 14 – 54 years.  
ASA score   ASA I                        
ASA II – III   
ASA IV - V  
An ordinal variable that indicates the patient’s physical health. Categorized as health = ASA I, Mild 
systemic disease = ASA II, severe disease but not incapacitating = ASA III, Incapacitating disease =ASA IV 
and moribund patient = ASA V  
Wound 
contamination 
1 = Clean (1 - 2)  
2 = Contaminated 
/Dirty  (3 - 4) 
A nominal variable representing the degree of contamination with 1 = no rupture of membranes and no 
labor, 2 = less than 2 hours of rupture of membranes and labor, 3 = rupture of membranes greater than 2 
hours and 4 = purulent amniotic fluid.  
Pre-operative 
hospitalization 
Number of days A continuous variable that refers to the number of days a patient stays in hospital before operation.  
Urgency of 
operation 
1= Elective                                
2 = Emergency  
A binary variable coded 1 for elective and 2 emergency 
Duration of 
Surgery 
1 = < 30 minutes        
2 = 31 – 60 minute    
3 = > 61 minutes 
An ordinal variable measuring the time of the operation and is divided into 3 categories: < 30 minutes, 31 -
60 minutes, 60+ minutes or greater than the 75th percentile (60 minutes). 
Antibiotic 
Prophylaxis 
Yes                          
No  
Binary variable which is considered as given or not.  
Regional 
Health Trust 
Helse Nord RHF            
Helse Vest RHF                        
Helse Sør-Øst RHF                   
Helse Midt-Norge 
RHF             
Nominal variables that refers to the four health regions of Norway 
Hospital size  1 = < 200 beds           
2 = 201 – 500 beds      
3 =    > 500 beds 
An ordinal variable referring to the size of the hospital in terms of bed capacity.  
Hospital type  1 = Primary                     
2   = Secondary               
3         =    Tertiary  
A nominal variable for the type of hospital coded 1 (primary), 2 (secondary) and 3(tertiary), 
 
SSI – Surgical Site Infection ; ASA - American Society of Anaestheologists ; NNIS - National Nosocomial Infections Surveillance systems ; NOIS - Norwegian Surveillance System for 
Healthcare-Associated Infections ; Helse Midt-Norge RHF – Central Norway Regional Health Trust ; Helse Nord RHF - North Norway Regional Health Trust; Helse Sør-Øst RHF – South 
– east Norway Regional Health Trust ; Helse Vest RHF – West Norway Regional Health Trust. 
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3.2.1 Statistical Methods for risk analysis 
Statistical analyses were carried out using Statistical Software (StataSE 13). The two 
continuous variables (age and preoperative hospitalization) were tested for normality using 
the SKtest and graphical methods – histograms and Q-Q plots. A two-sample t-test was 
carried out to test the mean age differences between those who developed SSI and those that 
did not. A Mann Whitney test was performed for the median difference in pre-operative 
hospitalization between those that had SSI and those that did not. For the rest of the nominal 
and ordinal variables, the Pearson’s Chi Square test was used to test for the differences in 
proportions across the two groups. A binary logistic regression model was used to identify 
the risk factors for SSI .A goodness of fit test was carried out using the Hosmer and 
Lemeshow’s method. All tests were analyzed as two tailed. Throughout the study, a P-value 
of < 0.05 was considered significant.  
The model: Equation [𝟔] 
𝒍𝒐𝒈𝒊𝒕 (𝑺𝑺𝑰) =  𝜷𝟎 + 𝜷𝟏𝐀𝐠𝐞 + 𝜷𝟐𝑨𝑺𝑨𝑰𝑰−𝑰𝑰𝑰 + 𝜷𝟐𝑨𝑺𝑨𝑰𝑽−𝑽 + 𝜷𝟑𝑾𝑪𝐜𝐥𝐞𝐚𝐧+ 𝜷𝟒𝐏𝐇 +
𝜷𝟓𝑼𝒐𝑺𝐞𝐥𝐞𝐜𝐭𝐢𝐯𝐞+ 𝜷𝟔𝑫𝒐𝑺𝟑𝟏−𝟔𝟎+ 𝜷𝟔𝑫𝒐𝑺>𝟔𝟎 +  𝜷𝟕𝑨𝑩𝒑𝐘𝐞𝐬 + 𝜷𝟖𝑹𝑯𝑨𝒗𝒆𝒔𝒕 + 𝜷𝟖𝑹𝑯𝑨𝐧𝐨𝐫𝐝 +
𝜷𝟖𝑹𝑯𝑨𝒎𝒊𝒅𝒕 + 𝜷𝟗𝑯𝒔𝒊𝒛𝒆𝟐𝟎𝟏−𝟓𝟎𝟎 + 𝜷𝟗𝑯𝒔𝒊𝒛𝒆>𝟓𝟎𝟎+𝜷𝟏𝟎𝑯𝒕𝒚𝒑𝒆𝐬𝐞𝐜𝐨𝐧𝐝𝐚𝐫𝐲+𝜷𝟏𝟎𝑯𝒕𝒚𝒑𝒆𝒕𝒆𝒓𝒕𝒊𝒂𝒓𝒚  
Where SSI was the binary indicator of infection status, WC was wound contamination, PH 
was preoperative hospitalization, UoS was urgency of surgery, DoS was duration of surgery, 
ABp was antibiotic prophylaxis, RHA was regional health authorities, Hsize was hospital 
size and Htype was hospital type.  
The logistic regression model estimated the log odds that a patient develops an SSI as a linear 
function of explanatory variables. The logit transformation was defined as the logged odds 
and refers to the ratio of the probability of SSI over the probability of no SSI, thus: 
𝑶𝒅𝒅𝒔 =  
𝒑
𝟏−𝒑
=
𝑷𝒓𝒐𝒃𝒂𝒃𝒊𝒍𝒊𝒕𝒚 𝒐𝒇 𝑺𝑺𝑰
𝒑𝒓𝒐𝒃𝒂𝒃𝒊𝒍𝒊𝒕𝒚 𝒐𝒇 𝒏𝒐 𝑺𝑺𝑰
= 𝒍𝒐𝒈𝒊𝒕 (𝑺𝑺𝑰 = 𝟏) = 𝒍𝒏
𝒑(𝑺𝑺𝑰)
𝟏−𝒑(𝑺𝑺𝑰)
                            [7] 
Odds ratios with 95% confidential interval can be calculated by taking the exponential of 
both sides of the regression equation. From the equation, when predictor variables increase 
by one unit, the odds increase by a factor of 𝑒𝛽 all else kept constant.  The factor 𝑒𝛽 is the 
odds ratio (OR) for the corresponding predictor variables and refers to the relative amount by 
which the odds of an outcome increase (OR >1) or decrease (OR <1) when the value of the 
predictor variable increase by one unit. 
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3.3 Cost analysis  
For the cost analysis, the variable infection status was categorized into four (no SSI, 
superficial SSI, deep SSI and organ/space SSI). This was done in order to estimate and 
compared costs across these four types of infections. The assumption behind categorizing 
infection status into four was that costs differed according to the depth of infection while risk 
was the same for all types of SSI.  
To capture direct medical costs associated with SSI after CS, we quantified the use of 
additional hospital resources by women with SSI during the two periods; the initial period of 
admission and the readmission period. Costs associated with the initial period were the cost 
of the initial surgery (NOK 52,117), estimated from the DRG 371 at unit cost of NOK 41,462 
and cost weight of 1.257, (DRG price list 2015). This cost was used as a baseline cost and 
applied to all women regardless of their infection status (no SSI, superficial SSI, deep SSI 
and organ/space SSI). Mean estimates for length of stay and reoperations were obtained from 
the NOIS register.  
Cost components for the readmission period were obtained from a questionnaire and used to 
quantify the additional physician time, drugs, laboratory and imaging services consumed by 
women with SSI in hospitals. A conceptual framework (clinical pathway) that depicted the 
women’ trajectory through the hospital from the day of readmission till the end of the 30-day 
surveillance period was adopted (Appendix 2). This was designed with guidance from my 
supervisors at Norwegian Institute of Public Health (NIPH) and the Department of Health 
Management and Health Economics at University of Oslo. It was then sent to four 
representative obstetricians/gynecologists in each of the four regional health trusts. The 
obstetricians/gynecologists were representing the different regions in the NOIS reference 
group.  Since there was considerable variation in the estimates from the gynecologists, the 
median point estimates were used (Appendix 3).  
Unit cost for physician time was estimated from the fee schedule for physician services while 
the cost per additional day in hospital was obtained from SAMDATA report of 2013. Unit 
costs for drugs and laboratory/imaging services were obtained from the Norwegian 
Medicines Agency and lovdata.no respectively. Costs for surgical interventions were 
estimated per DRG using the 2015 DRG price list (Table 4). 
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Table 4 Unit cost estimates (2015 Norwegian Kroner (NOK)) for cost drivers for surgical site infections 
after caesarian section. (September 2012 – December 2014). Norway 
Type of cost Type of unit Cost Cost (NOK) Fee/DRG number Reference 
Physician visit Cost/Visit 340   Fee schedule for physician services 
Additional length of stay per day Cost/episode of care  15,008      SAMDATA 2013 report 
Antibiotics*          
          Diclocil 500mg Cost/Pack of 30 171.92   Norwegians Medicines Agency 
         Gentamicine 80mg  Cost/Pack of 5  193.76   Norwegians Medicines Agency 
        Metronidazole 500mg  Cost/Pack of 20 800.56   Norwegians Medicines Agency 
Analgesic*          
       Paracetamol 500mg Cost/Pack of 20  21.52   Norwegians Medicines Agency 
       Ketorax 2.5mg  Cost/5 packs of 5 170.60   Norwegians Medicines Agency 
      Voltaren  50mg Cost/Pack of 50 127.20   Norwegians Medicines Agency 
      Pinex forte 30/500mg Cost/Pack of 20 87.50   Norwegians Medicines Agency 
Laboratory          
      Blood test (Leucocyte count & CRP)  Cost/test  54.00    Lovdata.no 
     Culture from infection site  Cost/test  50.00 Fee 704a   Lovdata.no 
Image diagnostics         
      Ultrasound examinations  Cost/ultrasound   362.00  UL2  Lovdata.no 
     CT scan  Cost/CT scan 952.00  CT2  Lovdata.no 
Surgical Interventions for SSI         
Conservative treatment at policlinic DRG weight 0.026 1,078  DRG 9140 DRG price list 2015 
Readmissions with conservative treatment with 
Vaccum Assisted Closure (VAC) 
DRG weight 0.645
   
26,742 DRG 376 DRG price list 2015 
     Readmissions with day surgery  DRG weight - 0,195  8,085  DRG 3770 DRG price list 2015 
     Readmissions with surgical intervention in 
hospital care  
DRG weight – 0.630  26,121 DRG 377N DRG price list 2015 
SSI = Surgical site infections; DRG = Diagnostic related Groups; * Antibiotics and analgesics were adjusted by the tax rate of 25%.  
3.3.1 Statistical methods for cost analysis 
The cost model included 6 cost drivers for the four types of SSIs (no SSI, superficial, deep 
and organ/space SSI). 
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The Model: 
𝑪𝒐𝒔𝒕𝒔 𝒐𝒇 𝑺𝑺𝑰 𝒂𝒇𝒕𝒆𝒓 𝑪𝑺 𝒑𝒆𝒓 𝒑𝒂𝒕𝒊𝒆𝒏𝒕 =   ∑ 𝑪𝒐𝒔𝒕 𝒇𝒐𝒓 𝒊𝒏𝒊𝒕𝒊𝒂𝒍 𝑪𝑺 + (𝑳𝑶𝑺 ∗ 𝑷𝒓𝒊𝒄𝒆/𝒅𝒂𝒚 + 𝑮𝑷 𝒗𝒊𝒔𝒊𝒕 ∗  
𝒉𝒐𝒖𝒓𝒔/𝒅𝒂𝒚 + 𝑫. 𝒕𝒆𝒔𝒕𝒔 ∗ 𝒄𝒐𝒔𝒕/𝒕𝒆𝒔𝒕 + 𝑫𝒓𝒖𝒈𝒔 ∗ 𝒄𝒐𝒔𝒕/𝒅𝒐𝒔𝒆 + 𝑺𝒖𝒓𝒈𝒆𝒓𝒚 ∗ 𝑫𝑹𝑮)                                                    
[𝟖] 
In the model above, the cost of one additional day in hospital (LOS) was computed on the 
basis of the mean cost of a day in Norwegian somatic hospitals, physician time (GP visit) was 
computed with the median number of physicians visits reported by the gynecologists, 
diagnostic tests including both laboratory tests and image diagnostics (D.tests) were 
computed on the basis of the reimbursement schedule per test, drugs were priced per dose at 
market prices after deducting 25% value added tax and costs for additional surgery were 
based on DRG cost weights.  
An independent sample t-test was performed to test the significance of the difference in costs 
between those with and without infections using cost data based on LOS. The cost data were 
not normally distributed and the Mann Whitney test would have been appropriate. However, 
due to the large sample size in the groups (18,928 for those with no SSI and 868 for those 
with SSI), t-tests were used. A one- way analysis of variance was used to compare and test 
whether the mean costs for the three types of SSI were significantly different (NOK 45,184 
for superficial SSI, NOK 137,122 for deep SSI and NOK 144,637 for organ/space infections). 
A non-parametric alternative to one-way ANOVA (Kruskal Wallis test) was also conducted 
to reaffirm the findings of the ANOVA test.                                                                                                                                                                                                                                               
3.4 Cost effectiveness analysis 
The 2008 revised Norwegian Society of Obstetrics and Gynecology guidelines recommend 
that only women considered to be at high risk of developing SSI should receive antibiotic 
prophylaxis. The high-risk category includes: emergency caesarian sections, long duration of 
surgery and severe hemorrhage. The current guidelines are compared to extended guidelines 
where all women undergoing CS receive antibiotic prophylaxis, regardless of their risk status.  
The antibiotic of choice for prophylaxis is either ampicillin or a second-generation 
cephalosporin
38
. In the analysis, ampicillin was used. The acquisition cost for a single dose of 
2 grams of ampicillin was NOK 54.80
50
. The type of antibiotic, dose and price were similar 
for the two groups. The only difference was in the proportion of women receiving the 
antibiotic prophylaxis. The cost for the initial surgery was NOK 52,117 (DRG 370). The 
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additional costs for specific types of SSI were obtained from the cost analysis. For superficial 
SSI, the extra cost was NOK 45,184 whilst for deep SSI it was NOK 137,122. The additional 
cost for organ/space infection was NOK 144,637 (Table 14).  
The measure of health benefit is one SSI avoided represented as 1 = SSI and 0 = no SSI.  
Transition probabilities were calculated from the proportions in Table 5. For the current 
guidelines, 63% (12,468 vs. 19,796) were high risk and received antibiotic prophylaxis whilst 
18% (3,629 vs 19,796) were low risk and did not receive antibiotic prophylaxis. A total of 
3,699 (19%) were lost to follow-up and thus not included in the model. For the high risk, 
95% had no SSI (11,811 vs. 12,468), 3.7% had superficial SSI (467 vs 12,468), 0.6% had 
deep SSI (85 vs 12,468) and 0.8% had organ/space SSI (106 vs 12,468). For the low risk 
group, 96% had no SSI (3,473 vs 3,629), 3.3% had superficial SSI (121 vs 3,629), 0.4% had 
deep SSI (17 vs 3629) and 4% had organ/space SSI (18 vs 3629).  
For the extended guidelines, the proportions for the high-risk group were similar to those 
from the current guidelines. The proportions for the low risk groups were adjusted by 40%
3
. 
Lamont et al
39
 estimates that routine use of antibiotic prophylaxis in caesarian section reduces 
the risk of SSI by 40 – 60%39. Estimates for the effects of routine use of antibiotics in 
caesarian sections were obtained from the literature. Data from the NOIS register was 
unsuitable for estimating the effects of antibiotic prophylaxis because antibiotic prophylaxis 
was provided to high-risk patients only. The NOIS data is not randomized hence the use of 
estimates from literature for the CEA model. With 40% reduction in the proportions for the 
low risk group with the extended guidelines, the likelihood of no SSI was 97.4% (3,535 vs 
3,629) and for superficial SSI it was 2% (73 vs 3,629). The likelihood of developing deep and 
organ/space infections was 0.3% for each type of SSI (11 vs 3629).  
 
 
 
 
 
                                                             
3 Routine use of antibiotic prophylaxis in caesarian section is estimated to reduce the risk of SSI by 40 – 60% (Lamont et al, 2011).  
26 
 
 Table 5 Proportion of women with surgical site infection among the high and low risk groups in Norway 
September 2012 – December 2014 (N= 19,796). 
Antibiotic 
prophylaxis 
No SSI                                                
(N= 18,928) 
Superficial SSI                        
(N= 629) 
Deep SSI                             
(N= 106) 
Organ/space SSI 
(N= 133) 
Total                       
(N= 19,796) 
Yes (%)                    
(High risk) 
11,811 (94.73) 467 (3.75) 85 (0.68) 105 (0.84) 12,468 (100) 
No (%)                 
(Low risk) 
3,473 (95.70) 121 (3.33) 17 (0.47) 18 (0.50) 3,629 (100) 
Missing 3,644 (98.44) 41 (1.16) 4 (0.11) 10 (0.28) 3,699 (100) 
Total 18,928 (95.58) 629 (3.21) 106 (0.54) 133 (0.68) 19,796 (100) 
 
3.4.1 Statistical Methods for CEA of antibiotic prophylaxis 
Using TreeAge Pro 2015, a decision analytic model was developed (Figure 6). The model 
looked at the cost effectiveness of antibiotic prophylaxis against SSI in caesarian sections for 
both high risk and low risk groups. In this cost effectiveness analysis the probability of 
developing SSI imposed by other risk factors such age, ASA class, urgency of operation and 
wound contamination were not factored in. Inclusion of all these variables would require a 
more complicated model than the decision tree employed here. In order to make simple, the 
CEA considered only the costs and effects of antibiotic prophylaxis with all other variables 
kept constant. Because of the short time horizon no discounting of costs was done in this 
study. 
Figure 6 Decision analytic model for CEA of antibiotic prophylaxis in caesarian section. 
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The costs for women who received antibiotic prophylaxis and developed SSI were calculated 
as:  
𝑪𝒐𝒔𝒕 𝒐𝒇 𝑺𝑺𝑰 = 𝑪𝒊𝒏𝒊𝒕𝒊𝒂𝒍 𝑺𝒖𝒓𝒈 + 𝑪𝑨𝑩 +  (𝑷𝒔𝒖𝒑 × 𝑪𝒔𝒖𝒑 +  𝑷𝒅𝒆𝒆𝒑 × 𝑪𝒅𝒆𝒆𝒑 + 𝑷𝒐/𝒔 × 𝑪𝒐/𝒔)                      
[9]  
Where  Cinitial Surg = cost of initial surgery,  CAB = cost of antibiotic prophylaxis, Psup= 
the probability of superficial SSI, Csup = Additional cost of superficial SSI,  Pdeep = 
probability of deep SSI, Cdeep = Additional cost for deep SSI, Po/s = probability of 
organ/space SSI and Co/s = Additional cost for organ/space SSI. The cost for women who did 
not receive antibiotic prophylaxis and did not develop SSI was for the initial surgery only 
(NOK 52,117), whilst those that received antibiotic prophylaxis had the cost of antibiotic 
included (NOK 52,117 + NOK 54.8). Table 6 shows the parameters included in the model. 
Table 6. Descriptions and valuations of Parameters used in the model (Costs, Effects and probabilities) 
 
Costs Value Description 
cAB 54.8 Acquisition cost for antibiotic 
cSurg 52,117 Cost for initial surgery 
CSupSSI 45,184 Additional costs for superficial SSI 
cDeepSSI 137,122 Additional costs for deep SSI 
cO/S_SSI 144,637 Additional costs for organ/space SSI 
Effects Values Descriptions 
SSI present 1 Women with SSI 
SSI not present 0 Women with no SSI 
Transition probabilities Values Descriptions 
pABp 0.63 Probability of receiving antibiotic 
pNoSSIHR 0.95 Probability of no SSI for the high risk groups 
pNoSSILR 0.96 Probability of no SSI for low risk group with current guidelines 
pNoSSILR 0.97 Probability of no SSI for low risk group with extended guidelines 
pSupSSIHR 0.04 Probability of developing superficial SSI for the high risk groups 
pSupSSILR 0.03 Probability of developing superficial SSI for low risk group with current guidelines 
pSupSSILR 0.02 Probability of developing superficial SSI for low risk group with extended guidelines 
pDeepSSIHR 0.007 Probability of developing deep SSI for high risk groups 
pDeepSSILR 0.005 Probability of developing deep SSI for low risk group with current guidelines 
pDeepSSILR 0.003 Probability of developing deep SSI for low risk group with extended guidelines 
pOS_SSIHR 0.008 Probability of developing organ/space infections for high risk groups 
pOS_SSILR 0.005 Probability of developing organ/space infection for low risk groups with the current guidelines 
pOS_SSILR 0.003 Probability of developing organ/space infection for low risk groups with the extended guidelines 
 
28 
 
Uncertainty in cost effectiveness analysis was analyzed by performing probabilistic 
sensitivity analysis (PSA). Sensitivity analysis examines both structural and parameter inputs 
in the model to see how they affect the model output. Implicitly, this affects the conclusion of 
the study. In probabilistic sensitivity analysis, a Monte Carlo simulation with 10,000 
simulations was performed using all the distributions in the model for all the 19,796 women. 
The societal willingness to pay for one SSI avoided was not estimated when performing 
Monte Carlo simulations. However, reference was made to a study done at Baerum hospital 
in Norway where the stated willingness to pay for one SSI avoided was NOK 18, 833
4
.  
The cost of antibiotic prophylaxis and the cost of initial surgery were fixed at NOK 54.8 and 
NOK 52,117 respectively. The number of women who underwent caesarian section (19,796) 
and those that received antibiotic prophylaxis (12,468) was large enough to allow their costs 
to be approximated to a normal distribution. The central limit theorem states that the 
sampling distribution of the mean will be normally distributed irrespective of the underlying 
distribution of the data with sufficient sample size
40
. Therefore a normal distribution was 
assumed for these two parameters. For both the cost of antibiotic and cost of initial surgery, a 
20% standard deviation
5
 was applied and the resulting inputs were a mean cost of NOK 54.8 
and standard deviation of 10.9 for the cost of antibiotic prophylaxis and NOK 52,117 as mean 
and a standard deviation of 10,423 for the cost of initial surgery (Figure 7 shows an example 
for the cost of antibiotic).  
                                                   
Figure 7 Normal distribution for the cost of antibiotic prophylaxis (NOK 54.8).  
                                                             
4 https://www.duo.uio.no/handle/10852/30295. Permanent link http://urn.nb.no/URN:NBN:no-32288  
5 Approximation of Standard deviation, Briggs et al, 2011, page 89 
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The gamma distribution is constrained over the interval 0 to positive infinity and was used to 
estimate uncertainty for the cost of the three types of SSI (Figure 8 shows an example for cost 
of deep SSI). The mean cost and standard deviation for each of the three types of SSI was 
obtained from the ANOVA results that compared the costs of the three types of SSI and used 
to analyze the cost difference between the three types of SSI (Table 14). 
 
                                                       
Figure 8 Gamma distributions for the costs of deep surgical site infections (Mean cost = NOK 197,601, 
Std.dev = NOK 124,343). 
 In TreeAge, gamma distribution is parameterized with the reciprocal of beta, (𝛽′ = 1/ 𝛽) and 
to fit a gamma distribution the mean and variance of the distribution can be represented by 
the alpha and beta (α,β) 40 .  The mean and variance of the gamma distribution can be 
expressed as functions of the alpha and beta parameters and calculated as follows
40
: 
                                    𝜶 =  
𝝁𝟐
𝒔𝟐
 ,     𝜷 =  
𝒔𝟐
𝝁
                                                                         [𝟏𝟎]     
The lognormal distribution was used to fit the data for effectiveness since effectiveness is 
bound by two states, the state of perfect health on one hand and the infinity state of worst 
possible health on the other. In the model this was represented as 0 for no SSI present and 1 
for SSI present. Women with SSI present were assigned a score of 1 regardless of the type of 
SSI (superficial, deep or organ/space).  The mean and standard error of the lognormal 
distribution were calculated from the relative risk of developing SSI using data from Table 5. 
Since the relative risk (RR) is calculated from ratios, the natural log scale can be used
40
.  The 
calculated mean and standard error of the lognormal distribution were 0.078 and 0.010 
respectively (Table 7).  
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𝐥𝐧(𝑹𝑹) = 𝐥𝐧(𝒂) − 𝐥𝐧(𝒂 + 𝒄) + 𝐥𝐧(𝒃 + 𝒅) − 𝐥𝐧(𝒃)                                      [𝟏𝟏] 
                   𝒔𝒆[𝐥𝐧 (𝑹𝑹)] =  √
𝟏
𝒂
− 
𝟏
𝒂+𝒄
+
𝟏
𝒃
−
𝟏
𝒃+𝒅   
                                                                 [𝟏𝟐]   
Where a = the proportion of women in the high-risk group with the current guidelines; b = 
the proportion of women in the high-risk group with the extended guidelines; a+c = the sum 
of women in the current guidelines and b+d = the sum of women in the extended guidelines.  
The beta distribution was used to fit the distribution for the probabilities of binomial data 
since it is constrained between 0 and 1
40
. In the study, it was used to fit the distribution for 
the probability of receiving antibiotic prophylaxis. Since the sample size (n) and the number 
of women receiving antibiotics (r) were known, the integer form is suitable for use to 
represent the beta distribution (α, β). With α set to r and β set to n- r, the distribution for the 
probability of receiving antibiotics and developing SSI was fit into the model. For both the 
current and extended guidelines, the beta distribution for the probability of receiving 
antibiotics was (12,468; 7,328), where α = 12,468 and represent the number of women who 
received antibiotic prophylaxis and β = 3,629 for those who did not receive antibiotic 
prophylaxis (Table 7). Equation 13 expresses the integer form of the Beta distribution: 
𝒇(𝒙) =  
(𝒏 − 𝟏)!
(𝒓 − 𝟏)! (𝒏 − 𝒓 − 𝟏)!
 𝒙𝒓−𝟏(𝟏 − 𝒙)𝒏−𝒓−𝟏                                  [𝟏𝟑] 
Where x = probability of receiving antibiotic prophylaxis; 𝑟 = α;  n − r = β  
A Dirichlet distribution was used to represent multinomial data on the terminal nodes. A 
Dirichlet distribution is a multivariate generalization of the beta distribution with parameters 
equal to the number of categories in the multinomial distribution
40
. In TreeAge, these 
distributions are represented as the number of women developing specific types of SSI. For 
the high risk group, the Dirichlet distribution for the probabilities of SSI was (11,811; 467; 
87; 106), where 11,811 represents the proportion with no SSI, 467 represents those who 
developed superficial SSI, 87 represents those who developed deep SSI and 106 represents 
those who developed organ/space infections (Table 7).  For the low risk group, the Dirichlet 
distribution for the probabilities of developing SSI was (3,473; 121; 17; 18). With the 
extended guideline, the Dirichlet distribution for the probabilities of developing SSI for the 
low risk group was (3535; 73; 11; 11).   
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Table 7 Description and valuation of distributions used to analyze uncertainty in the model for cost 
effectiveness analysis of antibiotic use in caesarian section.  
Normal 
distribution 
Value Mean Std.dev Description 
d_cSurg 52,117 52,117 10,423 Normal distribution for cost of initial surgery 
D_cAB 54.8 54.8 10.9 Normal distribution for cost of antibiotic 
Gamma 
distribution 
Value Mean Std. dev Alpha (𝛂) Beta (𝛃) Description 
d_cSupSSI 133,750 133,750 42,835 ((133,750) 2)/(42,835) 2) (133,750)/((42,835) 2) 
Gamma distribution 
for cost of superficial 
SSI 
d_cDeepSSI 197,601 197,601 124,343 ((197,601) 2)/((124,343) 2) (197,601)/((124,343) 2) 
Gamma distribution 
for cost of deep SSI 
d_cOS_SSI 211,095 211,095 108,784 ((211,095) 2)/((108,784) 2) (211,095)/((108,784)) 2 
Gamma distribution 
for cost of organ space 
SSI 
Lognormal                        
distribution 
Value Mean Std. dev Description 
d_RRSSI 1 0.078 0.010 Lognormal distribution for the relative risk of developing SSI 
Beta 
distributions 
Value 
Alpha 
(𝛂) 
Beta (𝛃) Description 
d_pABCP 12,468 12,468 7,328 
Beta distribution for the probability of receiving antibiotic prophylaxis for high 
risk groups 
Dirichlet 
distributions 
Value Dirichlet Description 
d_pSSIHR 11,811 (11,811;467;87;106) 
Dirichlet distribution for probability of superficial, deep and organ/space SSI in 
high risk groups 
d_pSSILR 3,473 (3,473; 121; 17; 18) 
Dirichlet distribution for probability of superficial, deep and organ/space 
SSI in low risk group with current guidelines 
d_pSSILR 3,535 (3,535; 73; 11; 11) 
Dirichlet distribution for probability of superficial, deep and organ/space 
SSI in low risk group with extended guidelines 
d_cSupSSI = distribution for costs of superficial SSI; d_cDeepSSI = distribution for costs of deep SSI; d_cO/S_SSI = distribution for costs 
of organ/space SSI.Std.dev = standard deviation  
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3.5 Ethical Considerations 
This study was a joint guideline between the University of Oslo (UiO) and the NIPH. On the 
part of UiO, this study was part of the master thesis and therefore permission to carry out the 
study was granted by the thesis committee. All university regulations pertaining to thesis 
writing were adhered to. At NIPH, the Norwegian Social Science Data Services (NSD) was 
notified about the thesis proposal and permission to access the data was granted by the Data 
Protection Officer for research.   
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4. Results                                                                                                                                                                    
Section 4.1 is devoted to the risk analysis of SSI after CS in Norway. Section 4.2 contains the 
results from the cost analysis and section 4.3 summarizes the results of the CEA of extending 
the provision of antibiotic prophylaxis to all women who underwent CS in Norway.  
4.1 Risk Analysis 
Of all caesarian sections (19,796) performed from September 2012 through December 2014, 
18,928 (95%) women had no SSI, 629 (3.17%) women developed superficial SSI, 106 
(0.53%) developed deep SSI and 133 (0.67%) developed organ/space infections. In total 868 
(4.4%) women satisfied the CDC definition of SSI and were matched against those that did 
not develop SSI (18 928). Of the 868 women who developed SSI, 72% were superficial, 12% 
deep and 15% organ/space infections.   
The mean number of days of hospitalization for women without SSI was 4.2 days and for 
women with SSI it was 5.1. When estimated against each type of SSI, the mean number of 
hospital days for women with superficial SSI was 4.5. For women with deep and organ/space 
SSI, it was 6.3 and 6.8 days respectively. A total of 170 (19.3%) women with SSI were re-
admitted based on their SSI status. Women with superficial SSI accounted for the majority of 
the re-admission 71(42.0%) and those with organ/space SSI were the second highest with 56 
(33.0%) re-admissions .43 (25%) of all readmissions were for deep SSI (Table 8).  
Table 8 Descriptive statistics for Women with Surgical Site Infections (N= 868) 
  Variable name 
Superficial infection                                                         
N= 629 
Deep infection                     
N= 106 
Organ/space infection   
N=133 
Total      
N= 868 
Number of SSI (% of total) 629 (72) 106 (12) 133 (15) 868 
Mean length of stay (s.d) 4.5 (2.9) 6.3 (4.6) 6.8 (5.1) 5.1 (2.6) 
Re-admissions (% of total) 71 (42.0) 43 (25.0) 56 (33.0) 170 (100) 
Re-operations (% total) 35 (33.0) 35 (33.0) 36 (34.0) 106 (100) 
SSI – Surgical Site Infection; SD – standard deviation 
Among the 170 re-admitted women, 62.0% (106) had re-operations. Most of the re-
operations were for organ/space infections (34.0%). Superficial and deep SSI each had a 
33.0% proportion of re-operations.  In comparison to re-admissions, 50.0% of all re-admitted 
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superficial SSI were re-operated and 64.0% of all re-admitted organ/space SSI were re-
operated. Deep SSI had the highest rate of re-operations after re-admission (81.0%).  
4.1.1 Patient Characteristics 
                          Table 9 Patient Characteristics (Caesarian Section) (N= 19 796) 
         * = Significant results; § = t-test; ϕ = Pearson’s Chi Square test; ASA = American Society of anesthesiologists; NNIS= National      
Nosocomial Infections Surveillance systems;   
The mean and median age of women who underwent CS in Norway during the study period 
(September 2012 – December 2014) was 31. The age range was from14 to 54 years. The 
majority of the women (73.0%) were classified as ASA I and II and only a few (less than 
0.01) were women with the least chance of surviving the surgical procedure (ASA IV-V). In 
terms of wound contamination, 60.0% of women had intact membranes and were not in labor 
(Class I) when the operation was done. Only 36.0% of those who developed an infection 
were in active labor or had membranes ruptured (Table 9).  
Patient Characteristics 
No infection                           
(N = 18 928) 
Infection                         
(N= 868 ) 
Total                                 
(N = 19 796) 
P-value 
Age (years)    0.9𝟒§ 
Mean  (s.d) 31.3 (5.4) 30.9 (5.5) 31 (0.2)  
Median 31 31 31  
Range 14 -54 18 - 48 14 -54  
ASA    0.5𝟒𝛟 
ASA I (%) 4 210 (95.3) 207 (4.7) 4 417 (100)  
ASA II-III (%) 13 771 (95.5) 648 (4.5) 14 419 (100)  
ASA IV-V (%) 21 (91.3) 2 (8.7) 23 (100)  
Missing (%) 910 (97.1) 27 (2.9) 937 (100)  
Total (%) 18 928 (95.3) 868 (4.7) 19 796 (100)  
Wound contamination    <0.0𝟓𝛟* 
Clean (%) 12 458 (95.9) 534 (4.1) 12 992 (100)  
Contaminated/dirty (%) 5 450 (94.5) 319 (5.5) 5 769 (100)  
Missing (%) 1 004 (97) 31(3.0) 1 035 (100)  
Total (%) 18 928 (95.3) 868 (4.7) 19 796 (100)  
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                         Table 10 Operational Characteristics of Caesarian Section (N= 19 796) 
Operational Characteristics 
No infection                     
(N = 18 928) 
Infection                         
(N= 868) 
Total                                 
(N = 19 796) 
P-value 
Time in hospital before surgery 
(days) 
   <0.0𝟓𝛡* 
Mean (s.d ) 1.1 (2.9) 1.2 (2.5) 1.1 (2.8)  
Median 0.0 1.0 0.0  
Min (Max) 0 (93) 0 (39) 0 (93)  
Urgency of operation    <0.0𝟓𝛟* 
Elective (%) 6 991     (96.5) 253 (3.5) 7 244 (100)  
Non elective (%) 11 920 (95.0) 631 (5.0) 12 551 (100)  
Total (%) 18 928 (95.5) 868 (4.5) 19 795 (100)  
Duration of operation    <0.0𝟓𝛟* 
< 30 minutes (%) 5 326 (96.1) 217 (3.9) 5 543 (100)  
31 – 60 minutes (%) 13 135 (95.3) 645 (4.7) 13 780 (100)  
> 60 minutes (%) 241 (92.7) 19 (7.3) 260 (100)  
Total (%) 18 702 (95.5) 881 (4.5) 19 583 (100)  
Antibiotic Prophylaxis    < 0.0𝟓𝛟* 
Yes (%) 11 811 (94.7) 657 (5.3) 12 468 (100)  
No (%) 3 473 (95.7) 156 (4.3) 3 629 (100)  
Missing (%) 3 628 (98.0) 71(1.9) 3 699 (100)  
Total (%) 18 928 (94.9) 868 (5.0) 19 796 (100)  
Length of stay    < 0.05ϖ 
Mean  (s.d) 4.2 (4.8) 5.1 (4.8) 4.2 (4.8)  
Median 4 4 4  
Min (Max) 0 (338) 0 (49) 0 (338)  
                 * = Significant results; ϖ = Wilcoxon Mann Whitney test; ϕ = Pearson’s Chi Square test 
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4.1.2 Operational Characteristics (Caesarian section) 
The average time from admission to operation was 1.1 days. For those who had an SSI, the 
average time was 1.2 days (std. dev 2.5). The majority of CSs were non-elective (63.4%). Of all 
the non-elective CS, 5.0% developed an SSI whilst 3.0% of the elective CS developed an SSI (p-
value <0.05). The average duration of surgery was 74 minutes for those without SSI and 78 
minutes for those with SSI (p-value <0.05). Antibiotic prophylaxis was given to 63.0% (12,468 
vs 19,796) of all CS and out of these 5.3% (657 vs 12,468) developed SSI. 18.0% (3,629 vs 
19.796), did not receive antibiotic prophylaxis and out of these 4.3% (156) developed SSI (p-
value <0.05). There were missing observations on antibiotic prophylaxis (3,699) representing 
19.0% of all CS. All operational characteristics were significantly associated with SSI as can be 
seen from Table 10. 
                    Table 11 Regional and Hospital Characteristics (Caesarian Section) (N= 19 796). Norway. 
Regional/Hospital characteristics 
No infection                     
(N = 18 928) 
Infection                         
(N= 868) 
Total                                 
(N = 19 796) 
P-value 
Regional Health Trust    < 0.05ϕ* 
Helse Midt-Norge RHF (%) 3 009 (95.5) 142 (4.5) 3 151 (100)  
Helse Nord RHF (%) 1 607 (93.7) 109 (6.4) 1 716 (100)  
Helse Sør-Øst RHF (%) 10 611 (95.7) 481 (4.3) 11 092 (100)  
Helse Vest RHF (%) 3 685 (96.0) 152 (3.9) 3 837 (100)  
Total (%) 18 928 (95.5) 868 (4.5) 19 796 (100)  
Hospital size    0.22ϕ 
< 200 beds capacity (%) 4 684 (95.3) 229 (4.7) 4 913 (100)  
201 – 500 beds capacity (%) 7 051 (94.9) 374 (5.0) 7 425 (100)  
> 500 beds capacity (%) 7 177 (96.2) 281 (3.8) 7 458 (100)  
Total 18 928 (95.5) 868 (4.5) 19 796 (100)  
Hospital type    0.77ϕ 
Primary (%) 4 372 (95.5) 204 (4.5) 4 576 (100)  
Secondary (%) 5 199 (95.7) 234 (4.3) 5 433 (100)  
Tertiary (%) 9 341 (95.5) 446 (4.5) 9 787 (100)  
Total (%) 18 928 (95.5) 868 (4.5) 19 796 (100)  
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4.1.3 Hospital characteristics  
Table 11 shows that hospitals in the Helse Sør-Øst RHF performed most of the CS (56.0%) 
and those in the Helse Nord RHF performed the least (8.6%). The overall infection 
proportion was 4.5% with the least (3.9%) in the Helse Vest RHF and the highest (6.3%) in 
the Helse Nord RHF.  Hospitals with bed capacity of less than 200 performed fewer CSs 
(2.4%) compared to those with higher bed capacity. Fewer SSI (3.7%) were reported in 
hospitals with bed capacity greater than 500 while hospitals with bed capacity of 201 to 500 
recorded the highest percentage of SSI (5.0%). Of all the SSIs, 26.0% were reported in 
hospitals with a bed capacity of less than 200 and 42% and 32% of all SSI were reported in 
hospitals with bed capacity of 201 – 500 and greater than 500 respectively. Tertiary hospitals 
performed most of the CSs (49%) and primary hospitals performed the least (23%). 
Secondary hospitals had the lowest incidence of SSI (4.3%) while tertiary hospitals had the 
highest (4.5%). In terms of the overall SSI, tertiary hospitals accounted for 50.4%, secondary 
hospitals 26.5% and primary hospitals 23.0%.  Only RHT showed a significance difference in 
proportion between those with SSI and those without. 
4.1.4 Bivariate and multivariate logistic regression  
In the bivariate logistic regression analysis described in Table 12, six variables were 
identified to be significantly associated with SSI (p-value < 0.05): Wound contamination 
(score 2+), Elective surgery, CS lasting 31 – 60 minutes and > 60 minutes, antibiotic 
prophylaxis, women residing in Helse Nord RHF.  Women with wound contamination score 
greater than 2 were more likely to develop SSI (OR 1.37; 95% 1.18 – 1.57; p-value <0.05) 
than those with wound contamination score of less than 2. Elective caesarian sections posed a 
lesser risk of SSI than non-elective (OR 0.68; 95% CI 0.59 -0.79; p-value <0.05).  Operations 
lasting > 60 minutes implied a 1.93 times higher odds than the base line operations lasting 
<30 minutes. Women receiving antibiotics were more likely to develop SSI compared to 
those that did not receive antibiotic prophylaxis (OR 1.23; 95% CI 1.03 – 1.48; p-value 0.01).  
Women residing in Helse Nord RHF had a 1.44 times higher odds of developing SSI than 
those in Helse Midt-Norge RHF.   
In the multivariate logistic regression, three independent risk factors for SSI after CS were 
identified as significant and these included ASA class IV & V, hospitals with bed capacity 
201 – 500 and secondary hospitals (Table 12).  
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                 Table 12 Bivariate and multivariate logistic regression output from Stata. (N = 868) 
 
Bivariate Logistic Regression Multivariate Logistic Regression 
Patient characteristic Odds ratio 95 % CI p-value Odds ratio 95% CI p-value 
Mean Age 0.99 0.98 - 1.00 0.13 1.00 0.98 - 1.03 0.90 
ASA 
      
ASA I 1   1   
ASA II and III 0.96 0.82 - 1.12 0.59 0.87 0.65 - 1.17 0.36 
ASA IV and V 1.94 0.45 - 8.32 0.37 11.49 1.02 - 129.46 0.05 
Wound contamination 
      
Contaminated (score 2+) 1.37 1.18 - 1.57 < 0.05 1.03 0.75 - 1.41 0.86 
Pre-operative hospitalization 1.01 0.99 - 1.03 0.26 1.00 0.96 - 1.06 0.73 
Urgency of surgery 
      
Elective 0.68 0.59 - 0.79 < 0.05 1.22 0.89 - 1.67 0.22 
Duration of Surgery 
      
< 30 minutes 1      
31 -60 minutes 1.21 1.03 - 1.41 0.02 1.27 0.91 - 1.78 0.15 
> 60 minutes 1.93 1.19 - 3.15 < 0.05 2.41 0.82 - 7.04 0.11 
Antibiotic prophylaxis 
      
Yes 1.23 1.03 – 1.48  0.01 1.01 0.69 - 1.48 0.92 
Regional Health Authorities 
      
Helse Midt-Norge RHF 1      
Helse Nord RHF 1.44 1.11 - 1.85 < 0.05 1.30 0.80 - 2.12 0.28 
Helse Sør-Øst RHF 0.96 0.79 - 1.16 0.68 1.19 0.78 - 1.80 0.41 
Helse Vest RHF 0.87 0.69 - 1.10 0.25 1.46 0.85 - 2.52 0.17 
Hospital size 
      
< 200 beds capacity 1 
  
1 
  
201 – 500 beds capacity 1.26 0.96 - 1.64 0.96 1.44 1.01 - 2.06 0.04 
> 500 beds capacity* 1 
  
1 
  
Hospital type 
      
Primary 1      
Secondary 0.96 0.79 - 1.17 0.71 2.30 1.36 - 3.89 < 0.05 
Tertiary 1.02 0.86 - 1.21 0.79 
   
            *Stata dropped the observations for these variables. ASA = American Society of Anesthesiologists; CI = confidence interval;  
                  Helse Midt-Norge RHF = Central Norway Regional Health Trust; Helse Nord RHF = North Norway Regional Health Trust; 
                  Helse Sør-Øst RHF = South –east Norway Regional Health Trust; Helse Vest RHF = West Norway regional Health Trust.  
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There was a marginal association between women classified as ASA IV and V with the risk 
of SSI (p-value <0.05). Keeping all other variables constant, women with ASA class IV and 
V had 11.49 times higher odds of developing SSI than women in the baseline line ASA class 
1. 
After adjusting for other variables, women operated in hospitals with bed capacity of 201 – 
500 were 1.44 times more likely to develop SSI compared to women operated in hospitals 
with bed capacity of less than 200. Of all the three significant variables in multivariate 
regression, secondary hospitals were the most significant (p-value <0.05). Women operated 
in secondary hospitals were 2.30 times more likely to develop SSI than those operated in 
primary hospitals (OR 2.30; 95% CI 1.36 -3.89).  
The model was tested for how well it fits the data using Hosmer Lemeshow method. The 
Hosmer Lemeshow measures how well the model is calibrated between the predicted and 
observed frequencies. An insignificant test result with a large P-value (0.42) was obtained, 
indicating a good fit.  
4.2. Cost Analysis    
The average cost of caesarian section for women without SSI was NOK 52,117 (DRG 371) 
and for women with SSI the average cost was NOK 124,321. The mean cost of SSI per 
patient was NOK 72,204 more than those without SSI (124,321 vs. 52,117). The cost per SSI 
for women with superficial SSI was NOK 97,301. For those with deep and organ/space SSI, 
the cost per SSI was NOK 189,329 and NOK 196,754 respectively (Table 13).  
The overall added cost for treating 642 superficial SSIs after caesarian section during the 
study period (September 2012 to December 2014) was NOK 29 008,128. During the same 
period, NOK 14 534,932 was used to treat deep SSI. Hospitals in Norway spent NOK 
19 670,632 in treating organ/space infections after caesarian section during the same period. 
In total NOK 63 213,692 was spent on treating all SSI during the study period.   
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                       Table 13 Estimates of additional costs per patient for the three types of SSI (N= 868) 
COSTS FOR SUPERFICIAL SSI (N=642) 
Cost driver Unit of care Unit estimate Unit Cost Total cost 
Initial Surgery DRG 371 1 52,117 52,117 
Length of stay Days 2.3* 15,008 36,019 
Reoperations DRG 3770 1 8,085 8,085 
Physician visit GP visit 1 340 340 
Laboratory tests Leucocyte count & CRP 2.5 54 135 
 Culture from infection site 1 50 50 
Diagnostic Imaging Ultra sound 1 362 362 
 CT scan 0 952 0 
Drugs Analgesics 3 days 21,52 21.52 
 Antibiotics 3-5 days 171,92 171.92 
 Total extra costs 45,184 
 Total costs with initial surgery 97,301 
COSTS FOR DEEP SSI (N=106) 
Initial Surgery DRG 371 1 52,117 52,117 
Length of stay Days 7.1* 15,008 106,556 
Reoperation DRG 376 1 26,742 26,742 
Physician visit GP visit 2 340 680 
Laboratory tests Leucocyte count & CRP 5 54 270 
 Culture from infection site 2 50 100 
Diagnostic Imaging Ultra sound 2 362 724 
 CT scan 1 952 952 
Drugs Analgesics > 3 days 127 127 
 Antibiotics > 5 days 971 971 
 Total extra costs 137,122 
 Total costs with initial surgery 189,239 
COSTS FOR ORGAN/SPACE SSI (N= 136) 
Initial Surgery DRG 371 1 52,117 52,117 
Length of stay Days 7.6* 15,008 114,060 
Reoperation DRG 377N 1 26,121 26,121 
Physician visit GP visits 3 340 1,020 
Laboratory tests Leucocyte count & CRP 6 54 324 
 Culture from infection site 2 50 100 
Diagnostic Imaging Ultra sound 2 362 724 
 CT scan 1 952 952 
Drugs Analgesics > 7 days 170 170 
 Antibiotics > 7 days 1,166 1,166 
 Total extra costs 144,637 
 Total costs with initial surgery 196,754 
SSI = Surgical site infections; NOK = Norwegian kroner; DRG = Diagnosis Related Groupings; C-RP= C-reactive protein; DRG 3770, 
weight = 0.195; DRG 376, weight = 0.645; DRG 377N, weight = 0.630;*Sum of estimates from the initial period and the readmission 
period 
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After dividing these costs into their component cost drivers, the most costly was the cost for 
staying in hospital (LOS), which accounted for an average of 78% of the total costs for all the 
three types of SSI (Figure 9). This was followed by cost for surgical interventions (18%) and 
the rest (2%). The costs per SSI associated with LOS were highest during the readmission 
period compared to the initial period. For superficial SSI, the costs per SSI for LOS were 
NOK 6,003 for the initial period compared to NOK 30,016 for the readmission period. For 
deep infections the costs per SSI associated with LOS was NOK 31,516 for the initial period 
compared to NOK 75,040 for the readmission period. A similar trend was observed for 
organ/space infection with the cost per SSI associated with LOS of NOK 39,020 for the 
initial period and NOK 75,040 for the readmission period. 
                                                  
LOS = Cost for length of stay; SI = Cost for surgical interventions; others = Physician costs, laboratory costs, Costs for diagnostic tests and drugs.                                                                                                                                                                                                   
Figure 9 Distribution of Costs for SSI according to cost drivers 
4.2.1 Comparing costs for women with and without SSI 
The results from the independent sample t-test indicate that there was a significant difference 
in costs between those with and without SSI (p-value < 0.05; 95% CI 62,013 – 64,086). The 
results are summarized in Table 14. The mean cost of LOS for women with SSI was higher 
(NOK 76,500) compared to the mean cost of LOS for women without SSI (NOK 63,050). 
The ANOVA results showed that the costs for the three types of SSI were significantly 
different from each other except for deep and organ/space infections. ANOVA results 
showed that organ/space infection had the highest costs compared to the baseline cost of 
superficial SSI.  
79% 
77% 
78% 
17% 
19% 
18% 
2% 
2% 
3% 
0 20000 40000 60000 80000 100000 120000
Superficial
Deep
Organ/space
NOK 
Others Reoperations LOS
42 
 
 
Table 14 Independent sample t-test for the difference in costs between women with SSI and without SSI 
and ANOVA test for the difference in cost between the three types of infections (N = 19,784). 
Results for Independent sample t-test 
Group Obs. Mean Std.Err. 95% Conf. Interval 
No SSI 18,900 63,050.28 528.87 62,013 – 64,086 
SSI 884 76,500.05 2,062.05 72,452 – 80,547 
Combined 19,784 63,651.25 513.94 62,643 – 64,658 
Diff 
 
-13,449.78 2,485.79 -18,322.14 - -8,577.41 
Pr (T) >  (t) = < 0.05 
Results for ANOVA test 
Cost Mean cost Std dev. t P > (t) 95% Conf. Interval 
Superficial 133,750 42,835 8.02 0.000 100,681 – 166,819 
Deep 197,601 124,343 2.71 0.008 17,084 – 210,617 
Organ/space 211,095 108,784 3.30 0.001 30,905 – 123,786 
Bartlett’s test for equal variance  
Between groups  P value = 0.0029 
Within groups  P value = < 0.05 
Pairwise comparison of means with equal variance  
 Contrast Std.Err. t P > |𝒕| 95% Conf. Interval 
Deep SSI vs Superficial 61,448 23,580 2.61 0.028 5,372 – 117,524 
Organ/space SSI vs Superficial SSI 76,203 23,416 3.25 0.004 20,518 – 131,888 
Organ/space SSI vs Deep SSI 14,755 23,416 0.63 0.804 -40,929 – 70,440 
      
                  SSI = Surgical Site infections                                                                                                                                     
4.3 Cost Effectiveness Analysis  
The TreeAge output (Figure 10) shows that the expected probability of SSI was higher with 
the current guidelines (0.05) compared to the extended guidelines (0.04). This translates into 
5 out of 100 caesarian sections ending up with a SSI in the current guidelines and 4 out of 
100 caesarian sections ending up with SSI in the extended guidelines. The health benefit was 
0.01 or 1 SSI per 100 caesarian sections. The expected cost per patient in the current 
guidelines (NOK 55,634) was higher compared to the extended guidelines (NOK 55,231). 
The extended guidelines were more effective (lower probability of SSI) and less costly 
compared to the current guidelines. 
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Table 15 The incremental cost –effectiveness ratio (ICER) for the current and extended guidelines of 
antibiotic prophylaxis (NOK 2015). 
Guideline Cost Effectiveness Cost - effectiveness Change in cost 
Change in 
effectiveness 
ICER 
Current Guideline 55,634 0.05    1 112,680 - -  
Extended Guideline 55,231 0.04    1 380,775 403 0.01 40,300 
       ICER = incremental cost effectiveness ratio 
The incremental cost-effectiveness ratio (ICER) was NOK 40,300 per SSI avoided. This 
means that if we choose to adopt the extended guidelines, we could save NOK 40,300 per 
avoided SSI (Table 15).  
 
 Figure 10 Decision Analytic model for CEA of antibiotic prophylaxis in caesarian section 
4.3.2 Probabilistic Sensitivity Analysis 
Probabilistic sensitivity analysis was performed to analyze the uncertainty surrounding the 
estimates of the expected incremental costs and expected incremental effects of the extended 
guidelines compared to the current guidelines of antibiotic prophylaxis in caesarian section. 
The incremental cost-effectiveness scatterplot (Figure 13) shows the spread of pairs of 
incremental costs and incremental effectiveness values (ICERs) from running 10,000 Monte 
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Carlo simulations. In the scatter plot, the differences in incremental costs and effectiveness 
between the two guidelines were used as base case point estimates (NOK -403; 0.01). From 
the scatterplot, 97.1% of the cost-effectiveness pairs fell on the southeast quadrant (II) (ICER 
<NOK 18,833), an indication that the extended guidelines are more effective and less costly 
that the current guidelines. This implies that the extended guideline dominates the current 
guidelines. 
The location of ICER points on the scatterplot indicates that there is some uncertainty with 
regards to the cost savings associated with the extended guidelines compared to the current 
guidelines. The uncertainty surrounding the cost savings range from NOK -900 to NOK150 
for the costs and 0.0025 to 0.012 for the effectiveness. This indicates a significant difference 
in costs and non-significant difference in effectiveness between the two guidelines.  
 
Figure 13. Incremental cost effectiveness scatterplot for the extended guidelines vs the current guidelines 
The CEAC (Figure 14) indicates the probability (on the y-axis) that the extended guidelines 
are cost-effective compared to the current guidelines given a range of willingness to pay (on 
the x-axis). The results are consistent with the findings from the incremental cost-
effectiveness scatterplot. At a willingness to pay of NOK 0 per SSI avoided, a total of 9,652 
cost-effectiveness points fell below the y-axis, indicating that the probability of the extended 
guidelines being cost-effective compared to the current guidelines was 0.96. When the stated 
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willingness to pay increased to NOK18, 833, a total of 9,712 cost-effectiveness points fall 
below the slope of the NOK 18,833 line. This implies that given the maximum willingness to 
pay of NOK 18,833 per SSI avoided, the probability that the extended guidelines are cost-
effective compared to the current guidelines increase to 0.97.  
 
 
       Figure 14 Cost-effectiveness acceptability curves for the two guidelines. 
The results of the cost-effectiveness analysis show that the extended guidelines significantly 
reduce SSI after ceasarian section compared to the current guidelines (0.01, CI: 0.0025 to 
0.012). The extended guidelines were also less costly than the current guidelines (NOK -403, 
CI: NOK -900 to NOK150).  
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5. Discussion  
In this chapter, I discuss three pertinent questions: What are the risk factors for SSI after 
caesarian section in Norwegian women? What are the hospital costs associated with SSI after 
caesarian section in Norway? How cost effective is it to extend antibiotic prophylaxis to all 
women undergoing caesarian section in Norway?  
5.1 Main findings and implications for risk analysis 
During the 28-month study period (September 2012 – December 2014), there were 868 SSI 
among 19,796 caesarian sections, representing a SSI rate of 4.4%. This translates into one in 
every 22 women who undergo caesarian section ending up with SSI. Compared to the SSI 
rate of 8.3% observed in 2007
24
, this represents a 3.7% reduction in SSI after caesarian 
section.  
Three independent risk factors for SSI after caesarian section were identified by multiple 
logistic regressions: ASA score greater than III, Hospitals with bed capacity of 201 – 500 and 
secondary care hospitals. These risk factors could be the target when designing and 
implementing preventive strategies for SSI after caesarian section in Norway.  The study 
findings show that women with ASA score greater than III were 11.5 times more likely to 
develop SSI than those with ASA score of 1. The ASA score accesses the physical health 
status of patients before surgery and a score greater than III indicates the presence of an 
incapacitating disease that is a constant threat to life. ASA score greater than III is associated 
with other factors that increase the risk of SSI such as increased duration of surgery, 
increased intra-operative blood loss and prolonged post-operative stay. This study finding was 
consistent with studies by Tran et al
26
 who showed that women with ASA score greater than 
III were 5.3 times more likely to develop SSI than those with ASA score of 1. However, a 
study done in England by Graham et al
42
 did not find any association between ASA score 
greater than III and SSI, neither did the study done in Norway by Eriksen et al
24
.   
The study findings show that women having caesarian sections in hospitals with bed capacity 
201–500 were 1.44 times more likely to develop SSI than those from hospitals with bed 
capacity of less than 200. We did not find any other studies done both in Norway and 
elsewhere that found hospital size to be significantly associated with SSI. However, our 
findings could be a result of hospitals with higher bed capacities having higher caesarian 
section rates and hence higher risk for SSI. Another probable explanation is that hospitals 
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with higher bed capacities receive patients with severe systemic illnesses (ASA score >III) 
from hospitals with less bed capacities. Hospitals with bed capacity less than 200 are not 
likely to offer specialized health care and thus refer patients with complicated or severe 
systemic illnesses to hospitals with much larger bed capacities. These referred patients are 
already predisposed to developing SSI. During the post-operative period, patients with 
complicated or severe systemic illnesses are likely to stay longer in hospital further 
increasing their odds for developing SSI.  
Secondary care hospitals had the lowest p-value in multivariate logistic regression. Having a 
caesarian section in a secondary care hospital was associated with an increased risk of SSI of 
2.3 times more compared to primary care hospitals. Similar to hospitals with bed capacity of 
201 – 500, secondary care hospitals are more likely to receive women with complicated 
conditions (ASA score > III) from primary care hospitals and thus perform more caesarian 
sections.  
5.2 Main findings and implications for the cost analysis 
Results from the cost analysis conducted in the study indicate a significant difference in costs 
between women with and without SSI. The results also show a significant difference in costs 
among the three types of SSIs except between deep and organ/space infections. Deep and 
organ/space infections both demanded longer hospital stay and required more resource 
intensive re-operations, hence the non-significant finding for the difference in costs.  Overall 
SSI results in up to NOK 35 million in costs every year. The costs of caesarian section for 
one patient with SSI were 2.4 times that of a patient without SSI. 
The finding of a significant difference in costs between those with and without SSI was 
consistent with the findings of several other studies
31, 36, 43
. As there was limited data on costs 
of surgical site infections after caesarian section in Norway to compare with, we looked at a 
cost-effectiveness analysis that was done at Bærum hospital (Norway) where the costs of SSI 
per patient were reduced by NOK 727.64 after implementing a quality improvement 
guideline
44
. In line with our study findings, the Bærum study indicated that SSI causes a 
significant economic burden on Norwegian health hospitals.  
In the study, the average cost per SSI was NOK 72,204. After comparing our study findings 
to that from other countries, we found similar costs of $ 3,500 (NOK 27,134) per SSI from a 
study done in the US by Olsen et al
36
. Costs associated with SSI increased with depth of 
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infection. The estimated extra costs per SSI ranged from NOK 45,184 for superficial SSI to 
NOK 137,122 for organ/space infection. This finding was in accordance with the findings 
from Urban et al
21
 and Olsen et al
45
. Urban et al
21
 found that the cost per SSI varied widely 
from $400 (NOK 3,235) for superficial SSI to $30,000 (NOK 242,677) for organ/space 
infections.  The costs of superficial SSI after caesarian section were lowest (NOK 45,184) 
and this was not surprising considering that most women with superficial infections required 
few or no interventions at all (Appendix 3). However the costs of organ/space infections were 
3 times higher than the costs of superficial SSI. The reason would be that organ/space 
infections demanded longer hospital stay (2.3 vs 7.6) and required more resource intensive 
procedures than superficial SSI (Table 14).  
The major cost driver in all the three types of infections was the cost of hospital stay (78%) 
and the least costly was the cost for laboratory tests (2%). Olsen et al
45
 found comparable 
results with 76% of the costs due to prolonged hospital stay. This finding is in line with the 
findings from risk analysis where women with ASA score > III were 11.5 times more likely 
to develop SSI. In terms of costs, such women are more likely to stay longer in hospital and 
consume more hospital resources than women with ASA score of 1.    
5.3 Main findings and implications for the cost-effectiveness analysis.  
The results of the cost effectiveness analysis show that the extended guideline was cost 
effective compared to the current guideline. With regards to the effectiveness, the probability 
of SSI was 5% with the current guidelines and 4% with the extended guidelines. In terms of 
costs, the current guidelines had higher costs per SSI avoided (NOK 55,632) compared to the 
extended guidelines (NOK 55,231).  With the extended guidelines, NOK 40,300 was spared 
for each SSI avoided compared to the current guidelines.  
The results of the probabilistic sensitivity analysis as summarized in the incremental cost-
effectiveness scatter plot (Figure 13) indicate that 97.1% of the ICER points fell on the south-
east quadrant below a stated willingness to pay of NOK 18,833. The CEAC indicated similar 
results with the probability of 0.97 that the extended guidelines were cost-effective compared 
to the current guidelines at all range of willingness to pay.  
The results of the cost-effectiveness analysis ought to be interpreted with caution considering 
that we adjusted the effects for the comparator using literature data external to the study. A 
randomization of patients receiving antibiotic prophylaxis would have produced more 
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reliable results that could have been used in the model. In this case we could not use the 
results from the study to incorporate the effects of antibiotic prophylaxis because the 
selection of patients was biased. Secondly, other factors such as the emergency of antibiotic 
resistant bacteria were not taken into consideration in the model. Providing routine antibiotic 
prophylaxis to all caesarian sections would increase the risk of developing resistant bacteria 
that are difficulty and costly to treat.  
5.4 Strength and limitations of the study 
The study has some strengths and limitations. First, the study used data from a regulatory 
surveillance register with 96% completeness. The completeness of the register provided a 
rich source of data for the study. For instance, from the register, we were able to get close 
approximations for hospital stay and re-operations.  
Secondly, the sample size was sufficiently big (19,769) to permit generalizability of the 
results to other settings within and outside Norway.  
The study had limitations with regards to the identification of the risk factors of SSI in 
caesarian section. The retrospective nature of the study makes it susceptible to the effects of 
biases and confounding. Even though we controlled for confounding in the multivariate 
regression, we still cannot infer causality of the identified risk factors in the study to SSI as 
other confounding factors maybe at play. We can therefore only correlate the risks identified 
to the outcome variable (SSI). There were missing observations in most of the variables and 
of particular concern was the number of missing observations on the antibiotic prophylaxis 
(18% or 3,699). It is likely that the loss to follow-up on the antibiotic prophylaxis had an 
influence on the significance of antibiotic prophylaxis in the analysis. In additional, the NOIS 
data proved unsuitable for analyzing the effects of antibiotic prophylaxis in caesarian section 
due to patient and treatment selection biases. NOIS data is not randomized and only high risk 
women receive antibiotic prophylaxis. Therefore the finding that antibiotic prophylaxis 
increases the odds of getting SSI was not unusual.  
The study also had a number of limitations in the cost analysis and notable among them was 
the hospital perspective adopted. Even-though we attempted to capture the costs of SSI after 
caesarian section in Norway, the hospital perspective provided a limited view as patient 
related costs and costs from other sectors were disregarded. A societal perspective would 
have provided a broader view of the costs of SSI after caesarian section. For instance, one of 
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the gynecologists who helped fill out the questionnaire noted that women with SSI demand a 
lot of emotional attention whose costs were unfortunately not captured in the study.  
Inclusion of DRG estimates for re-operations in the micro-cost analysis added certain 
limitations to the study results. Considering that the DRG approach is based on reimbursing 
the gross average costs and has the potential to omit other relevant costs involved in the 
treatment of SSI after caesarian section, our results could have been underestimated. Since, to 
our knowledge, there have not been similar studies on costs of SSI after caesarian section in 
Norway, we had little data to compare our results with locally. For this reason, the results of 
this study should be interpreted with some degree of caution.   
Furthermore, the three gynecologists who responded to the questionnaire on the clinical 
pathway were not representative enough. Their estimates varied widely and this rendered 
them to be less reliable. From the challenges we faced in interpreting their responses, we 
concluded that they (Gynecologists) too had difficulties in understanding the questionnaire. 
The example in point is where one gynecologist indicated the number of reoperations as a 
percentage of all the reoperations and the other gynecologist estimated it as the number of 
reoperations per patient per SSI.  In this case, interviews with the gynecologists would have 
been helpful. However, since the NOIS register captures no cost estimates, we had to make 
use of the clinical pathway and accept its inherent flaws.  
There were some limitations in the cost-effectiveness analysis. Firstly, we had limited time to 
complete our study and this time constraint was compounded by the delayed access to the 
data. Data for the cost-effectiveness analysis was based on the prior results of the risk and 
cost analyses conducted in the same study. This meant that the cost-analysis was done 
towards the end of the study period when time was of real essence. Secondly, we did not 
translate the intermediate outcome measure (SSI avoided) to a final measure such as quality 
adjusted life years (QALYs). The QALY would have represented the utility measure better 
than the intermediate outcome used.   
The study, through its limitations has opened up more opportunities for further research on 
the risk, cost and cost effectiveness analyses of SSI after caesarian section. There is need for 
further studies that will take on a societal perspective on the costs associated with SSI in 
Norway. And as data quality in the NOIS register continues to improve, there is need to 
incorporate cost data into the register. Future studies in CEA that go beyond simple decision 
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trees and can include all the other variables that we were not able to include would provide 
better and in-depth understanding of the costs and effectiveness of SSI interventions.  
5.5 Conclusion 
The study aimed at identifying risk factors for SSI after caesarian section, estimating the 
costs of these SSI and analyzing the cost-effectiveness of providing antibiotic prophylaxis to 
all women undergoing caesarian sections. For the risk factors, the multivariate logistic 
regression identified three risk factors for SSI after caesarian section. These are ASA score > 
III, hospitals with bed capacity between 200 – 500 and secondary care hospitals. These three 
risk factors could effectively be targets for prevention strategies for SSI after caesarian 
section. For the cost part, the study has provided a primary impression of the costs associated 
with SSI. The cost per caesarian section complicated with SSI was 2.4 times higher than 
uncomplicated caesarian section. For the cost effectiveness part, the study has indicated a 
97% chance of the extended guidelines being more cost effective compared to the current 
guidelines at the stated willingness to pay of NOK 18,833.  
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APPENDICES               
APPENDIX 1   Map of Norway showing the location of regional health authorities 
APPENDIX 2 Clinical pathway questionnaire used in estimating costs of SSI after CS. Please 
include information on patient interventions AFTER the caesarean section.  
Management Strategy Name of intervention Unit range Min –Max                       Patient Categories  
 
No infection Superficial SSI Deep SSI Organ/space SSI 
Laboratory Blood test 
 
Culture for infected site 
 
 
Other tests…………………. 
Min-max (number)     
Min-max 
(number) 
    
Min-max 
(number) 
    
Image diagnostics X-rays 
 
Ultrasound 
 
 
Others ……CT scan…… 
Min-max 
(number) 
    
Min-max 
(number) 
    
Min-max 
(number) 
    
Treatment of surgical site infection Number of dressing changes Min-max 
(number) 
    
Need for (yes/no):       
1. Advanced dressings 
 
 
2. Debridement 
 
 
3. Re-operation 
 
4. Others 
Type 
% needing 
    
DRG code 
% needing 
    
DRG code 
% needing 
 
 
    
 
% needing 
 
    
Medications (write down the 
names/dosage/days of administration) 
Analgesics type/ dose 
 
…Paracetamol &Diklofenak 
 
Dose & Days 
1 g x 4 
50 mg x 3 
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…Opiates…. 
 
Dose & days      
Antibiotics type/dose 
 
…Stable penicillin…….. 
 
 
…Sepsis regimen 
Mean Dose & Days  
 
 
 
   
Mean Dose & days      
Gynaecologist care  
 
Mean hours/day     
Re-hospitalization Length of stay for readmitted women  Min-max 
(days) 
    
Policlinic visits Number of policlinic visit Min-max 
(number) 
    
Any other cost driver not mentioned        
Any other cost driver not mentioned       
APPENDIX 3.  Calculated median values of the estimates from the gynecologists 
Additional Intervention  
Superficial SSI 
 
 
 
Deep SSI 
 
 
 
Organ /space SSI 
 
 
 
Gyn1 Gyn2 Gyn3 
Median 
estimate 
Gyn 1 Gyn 2 Gyn3 
Median 
estimate 
Gyn 1 Gyn 2 Gyn3 
Median 
estimate 
 
LOS for re-admitted women (days) 3 - 4 0 -1 0 - 3 2 3 - 4 3 - 10 0 - 5 5 3 - 4 3 - 10 0 - 5 5 
   
 
  
  
   
  
Physician care ( number of visits) 1 2 0 - 1 1 4 3 0 - 3 2 4 5 0 - 2 3 
   
 
  
  
   
  
Nursing care 3 - 4 
not 
included 
Not 
included 
Not 
included 
3 - 4 
not 
included 
Not 
included 
Not 
included 
3 - 4 
Not 
included 
Not 
included 
Not 
included 
   
 
  
  
   
  
Laboratory 
  
 
  
  
   
  
Blood test ( CRP & Leucocyte 
count) 
1- 5 0 - 2 1 - 5 2.5 5 - 10 1 - 3 2 - 10 5 5 - 10 2 - 4 2 - 10 6 
Culture from infection site 1 1 1 -2 1 2 1 - 3 1 -3 2 1 2 - 4 1 - 3 2 
   
 
  
  
   
  
Image diagnostics 
  
 
  
  
   
  
Ultrasound 1 - 2 1 0-1 1 2 1 -  3 1-2 2 2 - 5 3 1 - 3 2 
CT scan 0 0  0 1 - 2 0 - 2  1 0 -  1 1 - 2  1 
   
 
  
  
   
  
Medications Usual dose 
 
 
 
Higher dose   
 
Higher dose 
 
  
Analgesics 
  
 
  
  
   
  
Paracetamol  500mg *3*7 1 - 7 days 0 3 – 15 days 
Paracetamo
l for 3 days 
1 -7 days  3 – 15 days 
 
1 - 7 days 3 – 15 days   
Ketorax 1- 3 days 0  
 
1 - 7 days   
 
1 - 7 days 
 
 
Ketorax for 
3 days 
Voltaren 1 -3  days 0 0 – 5day 
 
1 - 3 days 0 – 10days  
Voltaren for 
3 days 
1 - 7 days 0 - 10   
Pinex Forte 1 - 3 days 0  
 
1 - 3 days   
   
  
   
 
  
  
   
  
Antibiotics 
Triple 
Antibiotics 
Mono 
antibiotic 
Mono 
antibiotic 
Mono 
antibiotic 
Triple 
Antibiotics 
Double 
antibiotics 
 
Double 
antibiotics 
Triple 
Antibiotics 
Double 
antibiotics 
Triple 
antibiotics 
Triple 
antibiotic 
 
Surgical Interventions for SSI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
Number of usual dressing 3 - 7 0 1 - 15 7.5 3 - 7 3 1 - 15 9 0 - 2 1 -2 0 1 
Advanced dressing – VAC           ( 
Yes/No) 
Yes No No Yes Yes 
Spriking i 
sårel (0-1) 
Maybe YES NO NO Maybe NO 
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Re-operation 2 - 4 0 - 3 2 -  4 0 2-4 3 1 - 2 1 2-4 3 
   
 
  
  
   
  
Policlinic follow up 3 - 4 1 0 - 7 4 3 -  4 3 0 2 0 - 4 2 0 2 
   
 
  
  
   
  
Mental health 
  
 
  
 
    
  
Gyn = Gynecologist; CRP = C- reactive protein; LOS = length of stay; VAC = Vacuum Assisted Closure; Triple antibiotics include a 
penicillin. Aminoglycoside and flagyl; double antibiotics include a penicillin or cephalosporin with flagyl; Mono antibiotic included 
Diclocil only.  
      
 
